header logo image


Page 3«..2345..»

Archive for the ‘Stem Cell Panama’ Category

Stem Cell Therapy for Autism at the Panama Stem Cell Institute

Saturday, September 14th, 2019

May 2019

Parents Guide to Cord Blood Foundation interview with Dr. Neil Riordan

The founder of Parents Guide to Cord Blood Foundation, Dr. Verter, had the opportunity to interview Dr. Riordan, the founder of the Panama Stem Cell Institute, during the annual meeting of the Perinatal Stem Cell Society in March 2019. This coverage is important for parents because it provides a concise summary of the Panama protocol for autism treatment. For cord blood bankers, this illustrates some factors that can contribute to a successful stem cell clinic.

This interview does not constitute an endorsement of the Panama Stem Cell Institute.

Many parents today are seeking stem cell therapy for a child with autism at the Stem Cell Institute located in downtown Panama City. The Panama Stem Cell Institute was founded by Neil Riordan PA PhD. Dr. Riordan is also a founder of the Riordan Medical Institute in Texas, and is involved with several companies in the field of regenerative medicine.

The popularity of the Stem Cell Institute in Panama arises from several factors. The clinic provides therapies using specially screened and processed mesenchymal stem cells (MSC) sourced from umbilical cord (UC) tissue that has been donated after normal, healthy births. These UC-MSC can safely be given to patients without any matching to the donor. Since the Stem Cell Institute does not use cord blood, parents do not have to worry about whether they banked cord blood for their children, whether the cord blood they banked is viable, or how to ship the cord blood to Panama. Once accepted and scheduled for treatment, the family travels to Panama and the clinic provides the stem cells. Both the clinic and accompanying laboratory in Panama are fully licensed by the national medical authorities and adhere to international standards. Parents can feel confident that the therapy is legal, the stem cells are sourced and prepared in an affiliated laboratory, and the clinic is highly experienced. The waiting list at Panama is only a few months, which is important to parents who want to try stem cell therapy while their childs brain is still developing.

The Stem Cell Institute provides families with a comprehensive five-day package that includes expedited customs clearance and a hotel room at the Hilton, which is connected to the clinics office tower. The price ranges from around $13,000 to $18,000 depending on the childs weight. For children with autism, the first day of the treatment, a Monday, is dedicated to intake testing. On days Tuesday through Friday, the child receives daily intravenous infusions of stem cells suspended in sterile solution. The four infusions deliver a total dosage of 40 to 80 million UC-MSC, depending on the childs weight.

The safety profile of the Panama Stem Cell Institute is well established. Since the clinic opened in 2006, they have performed over 10,000 procedures, and currently they are treating up to 200 patients per month. A patient registry safety review performed over nine months in 2018 found 497 adverse events (AE) out of 3058 treatments administered, which is a rate of 16.2%. The vast majority of AE (15.8%) were mild symptoms, consisting of fatigue and headache. The worst AE, consisting of nausea and vomiting, were only reported by 0.13% of patients.

A clinical trial for autism, registered by the clinic in 2014, has been completed with 20 participants. A paper was submitted to a peer-reviewed medical journal and is currently under review. In the final paper, outcomes were measured using Autism Treatment Evaluation Checklist (ATEC) scores, Childhood Autism Rating Scale (CARS) scores, macrophage-derived chemokine (MDC) levels and activation-regulated chemokine (TARC) levels recorded at baseline and again at 13 weeks, 25 weeks, 37 weeks, 49 weeks, and 89 weeks post-therapy.

At the Perinatal Stem Cell Society meeting, Dr. Riordan presented data on 47 autism patients selected from the clinic patient registry (movie link at bottom of the page). Among these patients, 87% were boys, the median patient age was 7 years old, and the daily dose averaged 15.75 million UC-MSC. For these patients, ATEC scores were compared at baseline and six months. The scores showed improvements in the categories of speech, sociability, awareness, and behavior; and all of the improvements had high statistical significance.

Parents contemplating autism therapy at Panama are encouraged to rule out other conditions that can cause autism symptoms, such as genetic disorders and heavy metal poisoning. Normal blood test readings for heavy metals are mandatory before enrolling for therapy.

Parents wishing to learn more about autism therapy at the Stem Cell Institute in Panama can visit the autism treatment page on the clinic website. There is an unaffiliated Facebook group, Stem Cell Therapy for Autism, which is run by parents for parents as a forum to share experiences with stem cell therapy.

Parents Guide to Cord Blood Foundation explains the rationale behind autism therapy with either cord blood MNC or cord tissue MSC in our companion article, Everything parents should know about stem cell therapy for Autism.

View original post here:
Stem Cell Therapy for Autism at the Panama Stem Cell Institute

Read More...

Cost of Stem Cell Transplant – Beike Biotechnology

Saturday, September 14th, 2019

Stem cell treatment is regularly in the news around the world. Mostly the topics revolve around safety, efficacy, or ethics. health insurance, Lately however, the price of these treatments has also been highlighted. Our stem cell provider,Beike Biotechnology, recently released their new stem cell therapy protocol in hopes of cutting treatment cost.

Other treatment providers in the news have been advertising prices from 50,000 USD to 200,000 USD.

Despite the thousands of positive research papers and clinical trials showing the effectiveness of stem cells the treatment is not readily available in most countries, especially not at a reasonable price. In the USA for example, it is possible to receive a stem cell treatment for Multiple Sclerosis. The bad news is that it will cost around $125,000 per patient, not including any drugs or supportive therapies. Also, this type of cell therapy (hematopoietic stem cell transplant) is not effective in progressive MS.

Similarly, a New Zealand man with Multiple Sclerosis is traveling to Singapore for hematopoietic stem cell treatment. The cost of this treatment is $200,000. Also, according to Associate Professor Bronwen Connor from Auckland University, in regards to hematopoietic stem cell transplants international trials showed the symptoms could recur over time and there were also some deaths associated with the treatment that were higher than would be acceptable for clinical practice.

Our treatment, specifically the new protocol from Beike Biotechnology was designed with progressive conditions in mind and utilizes umbilical cord blood and mesenchymal adult stem cells, which have had no history of adverse side-effects in thousands of clinical trials and treatments.

Another news story highlighted a Spinal Cord Injury (SCI) patient who paid $50,000 for a treatment in Panama. At this time this patient has not seen any significant improvements.

Our medical team recommends extensive physical and occupational therapy in combination with stem cell treatment for Spinal Cord Injury SCI which is offered at our partner treatment center Better Being Hospital. Our stem cell treatment protocol includes 6 injections of umbilical cord mesenchymal stem cells over 25 days with intensive rehabilitation is almost half Panamasstem cell institute cost which is $31,000.

Also, late last year spinal epidural stimulation, in combination with stem cell therapy, was found to be a very effective treatment option for SCI, allowing patients to voluntarily move their previously paralyzed limbs. In total, our comprehensive stem cell + epidural stimulation treatment is less than $80,000 for a 45 day intensive rehabilitation.

Our comprehensive treatment using umbilical cord stem cellsstarts at $12,000. For detailed information regarding our treatment packages

Excerpt from:
Cost of Stem Cell Transplant - Beike Biotechnology

Read More...

What Stem Cell Clinics Do You Trust? | BioInformant

Saturday, May 4th, 2019

Be in the know about leading stem cell centers you can trust in this article.

In this article:

Stem cell clinics have received a great deal of negativepress,with prominent media outlets announcing that the Food and Drug Administration (FDA) had mailed Warning Letters to stem cell centers across the United States.According to a paper published in the journalCell Stem Cell in June 2016,at least 351 businesses offer unproven stem cell interventions fromclinics spread across the U.S.

Shortly after publication, the MIT Technology Reviewand Washington Postpicked up the story, spreading the fear far and wide.Journalists then got enthralled with the story, calling it the Wild West of stem cells.

But, is this the whole story?

What this hype does not cover isthe promising medical potentialof stem celltherapies, nor had it properly credited the legitimate stem cell clinics that comply with FDA regulations to offer effective medical treatments to populations of patients who otherwise have limited options.

Today, the majority of medical clinics that offer stem cell treatments administer mesenchymal stem cells (MSCs), which they source from human fat (adipose tissue) orbone marrow.

Mesenchymal stem cells are a type of multipotent stem cell that is administered for a range of medical applications, including orthopedic repair, pain management, arthritis, and asthma.

When properly administered, multipotent self-derived stem cells (such as MSCs) can be safe for patient use.

It is important that the cells be multipotent (limited in their differentiation capacity), rather than totipotent (can become any cell) or pluripotent (can become most cells). There is also an additional level of safety that comes from having stem cells be self-derived, which doctors and scientists call autologous.

Stem cell differentiation capacity is explained below:

While it is true that many stem cell centers are not properly regulated, the therapeutic promise of stem cells is also clear.

Today, nearly 30,000 scientific publicationshighlight research and therapeutic advanceswith mesenchymal stem cells (MSCs), and approximately850+ clinical trials are investigating therapeutic uses of MSCs. Additionally, 300,000+ scientific publications about stem cells have been released.

This momentum is not surprising, because We are not made of drugs, we are made of cells.

However, the biggest issue with the hype surrounding stem cell centers is that it does not give proper credit to the companies that cooperate with regulatory bodiesto ensure a safe and efficacious patient experience. Many of these companies also collaborate withoffshore regulatory bodies to offer stem cell procedures approved by local regulatory agencies.

The FDAsCenter for Biologics Evaluation and Research (CBER)regulates human cell and tissue-based products in the U.S., known as HCT/Ps. The FDA has two different paths for cell therapies based on relative risk.

These pathways are commonly called 361 and 351 products.

The 361 products that meet all the criteria in 21 CFR 1271.10(a)are regulated as HCT/Ps and are not required to be licensed or approved by the FDA. These products are called 361 products because they are regulated under Section 361 of the Public Health Service (PHS) Act.

In contrast, if a cell therapy product doesnot meet all the criteria outlined in 21 CFR 1271.10(a), then it is regulated as a drug, device, or a biological product under the Federal Food, Drug, and Cosmetic Act (FDCA) and Section 351 of the PHS Act.[1]

These 351 products requireclinical trials to demonstrate safety and efficacy in a process that is nearly identical to that what is required for pharmaceutical products to enter the marketplace.

Stem cell centers must ensure that their treatments meet the FDAs criteria to be classified as 351 products.

Below, we cover five leading stem cell centers. Each one has treated large populations of patients with adult stem cells. At least one (Regenexx) is maintaining a Patient Registry to document long-term patient outcomes.

We are not advising patients to seek treatments from these companies.We are identifying them to allow readers to seek out more information.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert and visionary, the Stem Cell Institute in Panama is among the worlds leaders in stem cell research and therapy. Their treatments focus on well-targeted combinations of allogeneic umbilical cord stem cells, as well as autologous bone marrow stem cells.

The stem cells clinic uses stem cell therapies to treat various ailments, including the following:

One of their most recent studies exhibited the clinical feasibility of stem cell transplant process as a safe and effective treatment approach for patients with multiple sclerosis (MS).

Published in the Journal of Translational Medicine, the study showed that umbilical cord stem cells can slow down MS disease progression and decrease the frequency of flare-ups.

However, these stem cells did not exhibit the ability to repair damaged nerve cells or myelin sheaths.

After the completion of this clinical study, there was an improvement in MS patient disability. The 1-month mark of the study documented improvements in mobility, hand, bladder, bowel, and sexual functions. Importantly, the study demonstrated that a sustained one-year umbilical cord stem cell therapy has more durable benefits than current MS drug therapies.

Headquartered in Denver, CO, Regenexx offers self-derived (autologous transplant) same-day stem cell treatments to patients with orthopedic injuries and conditions. Regenexx clinicsincorporate a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments.

TheRegenexx technologyinvolvesa procedure in whicha small bone marrow sample is extracted through a needle and blood is drawn from a vein in the arm. These samples are then processed in a laboratory and the cells they contain are injected into the area needing repair, with the goal of delivering large numbers of stem cells to the site of injury.

Regenexx is also a licensedoffshore clinic in the Cayman Islands where patients can undergo treatments that utilize laboratory-expanded (ex vivo) stem cell populations. This approach allows for a much larger number of stem cells to be administered to the patient than is supported by U.S. law, which currently prohibits laboratory procedures that the FDA considers to exceed minimal manipulation.

Dr. Christopher Centenois the Founder and CEO of Regenexx. He is a global authority in the culture expansion and clinical use of adult stem cells to treat orthopedic injuries and thevisionary behind the Regenexx technology.

I am also a Regenexx patient.Click here to read my experience.

Founded in 2011,Okyanosis a stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic degenerative conditions. Okyanos Cell Therapy uses internationally-approved technology to deliver a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) to patients with conditions such as the following:

Okyanos maintains both a North American Office in Clearwater, FL, and a purpose-built Cell Therapy Surgical Center inFreeport, GrandBahama. Okyanos stem cell treatments are performed in their state-of-the-art surgical centers under the care of board-certified doctors.

Okyanos is also fully licensed and regulated under the Bahamas Stem Cell Therapy and Research Actand adheres to U.S. surgical center standards. Click here to access our recent interview withMatthew Feshbach, Co-Founder and CEO of Okyanos.

The Global Institute of Stem Cell Therapy and Research (GIOSTAR) provides adult stem cells for autologous and allogeneic stem cell therapy to patients around the world, based on research byDr. Anand Srivastava. The stem cell clinic offers adult stem cells for rejuvenation treatment, muscular injuries, and degenerative diseases.

Each of GIOSTARs clinics is licensed for the application of stem cell therapy.Since 2000, its team of scientists and clinicians have been developing and utilizing stem cell-based clinical protocols for the purpose of stem cell treatment.

Although the company is headquartered in San Diego, California, GIOSTAR Mexico has provided stem cell therapy to patients from all over the world. Mexicos regulation of stem cell therapeutics differs from the regulations imposed by the U.S. FDA, making it a growing site for medical tourism.

Celltex specializes in cryopreserving mesenchymal stem cells (MSCs) for therapeutic use. Celltex acquires stem cells by collecting a small fat sample from a patient, from which MSCs are extracted,isolated, multiplied, and stored for future use (known as cell banking).

Patients can then use their stored stem cells for regenerative purposesthrough infusions or injections performed by a licensed physician.

Because the FDA considers an individuals stem cells a drug if they have been expanded in large quantities, Celltex has begun the process of undertaking clinical trials on stem cells as a treatment for a range of medical conditions, seeking approval from the FDA to allow physicians to utilize these cells.

Nonetheless, to meet the immediate needs of its clients, the company also has taken steps to meet the requirements of the FDA and COFEPRIS, a Mexican institution equivalent to FDA in MSCs import and export.

Celltex also works with Mexican hospitals that are established and certified that allowed the companys cell-banking clients to receive their stem cells for medical purposes.

Although these leading stem cell centers have built a good reputation in regenerative medicine, it is still important to probe these clinics before the proper procedure. These questions should cover what to expect from the treatment, safety and emergencies, cost, and the patients rights.

Treatment

Safety and Emergencies

Costs

Patients Rights

Understanding how these leading stem cell centers operate and what they do allows the patient to assess which of them is the right investment. While the information above is important to understand from a scientific and regulatory perspective, patient experiences are valuable too.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Have you had a stem cell transplant?What stem cell clinic did you use? What treatment did you get and for what condition? Share your answers in the comments below.

Footnotes [1] Aabb.org. (2017). Cellular Therapies. [online] Available at: http://www.aabb.org/advocacy/regulatorygovernment/ct/Pages/default.aspx [Accessed 1 Aug. 2017].

What Stem Cell Clinics Do You Trust?

Here is the original post:
What Stem Cell Clinics Do You Trust? | BioInformant

Read More...

Human Umbilical Cord Stem Cells for … – Medistem Panama

Wednesday, February 6th, 2019

Abstract

Osteoarthritis (OA) is a chronic degenerative condition of the articular cartilage, which is the most common cause of disability in patients over age 65. Treatment options are limited towards alleviating symptomology.

Mesenchymal stem cells (MSC) are effective at treating osteoarthritis (OA) in animal models and clinical trials [1-6]. Mechanisms of therapeutic activity appear to be associated with regenerative and anti-inflammatory factors produced by MSC [7, 8]. On the one hand, MSC produce soluble factors that are antioxidant [9], antifibrotic [10], and stimulate endogenous chondrogenic progenitors [11], on the other hand MSC directly can differentiate into cartilage tissue [12].

The proposed study will involve intra-articular injection of umbilical cord tissue mesenchymal stem cells (UC-MSC) into joints of 20 patients with grade 2-4 radiographic OA severity and intravenously in 20 patients with grade 2-4 radiographic OA severity. The primary endpoint will be safety and feasibility as assessed by lack of treatment associated adverse events. The secondary endpoint will be improvements in joint function as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Patients will be examined at baseline and 3 and 12 months after treatment.

This, study will provide support for double-blind placebo controlled investigations. The potential of using UC-MSC for this debilitating condition will open the door for future investigations in other inflammatory conditions if results demonstrate safety and feasibility of this approach.

Follow this link:
Human Umbilical Cord Stem Cells for ... - Medistem Panama

Read More...

The Cost Of Stem Cell Therapy And Why It’s So Expensive …

Monday, February 4th, 2019

How much is stem cell therapy? As stated by CBC Canada,the cost of stem cell therapy is $5,000 to $8,000per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher. Our May 2018 poll found that stem cell treatments can cost as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of theclinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.

In this article:

Stem cell therapy is the use of living cells as therapeutics to treat disease or injury. Read on to learn about the cost requirements of these procedures.

CBC Canadas pricing involves Cell Surgical Network (CSN) following its protocol to remove fat tissue and process it before re-injecting [adipose-derived stem cells] either directly or intravenously into the same patient. Unfortunately, the U.S. FDA and Department of Justice (DOJ) sent this network of stem cell treatment providers a permanent injunction notice in May 2018. Therefore, patients should not seek treatments from the group at this time.Although Cell Surgical Network (CSN) is based in California, it has a network of approximately 100 U.S. treatment centers. They also have three Canadian clinics located in Vancouver, Sudbury,andKamloops.

The controversy such as the one above stirs up questions about the safety of stem cell procedures. Anyone considering stem cell therapy from any tissue or source will benefit from understanding the possible consequences of stem cell therapy and the factors driving costs.

For the patient, a stem cell transplant involves multiple steps, including:

There are also real costs for the doctors who provide stem cell treatments. They have overhead costs, including:

There is also time and expertise required toperform the procedure and offer post-operative care. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivery technologies.

Stem cell treatment has gained more and more traction over the last decade. It has been helped along by considerable advances in research. In 2017, the number of scientific publications about stem cells surpassed 300,000. The number of stem cell clinical trials has also surpassed4,600 worldwide.

However, stem cell therapy is still expensive. Among the cheapest and easiest options is to harvest adipose-derived stem cells (ADSCs) those that exist in adult fat layers and re-deliver them to the patient. Unlike harvesting from bone marrow or teeth, providers can feasibly remove fat, separate stem cells, then re-inject them into a patient the same day. This approach is typically less expensive than those that require more invasive procedures for harvesting. Because of its practicality in terms of cost, it has become a common approach to stem cell treatment.

Relatively easy harvesting stilldoesnt translate to inexpensive cost, although some are certainly more affordable than others. For orthopedic conditions, the costof stem cell therapy is typically lower, averaging between $5,000 and $8,000. Examples of these types of medical conditions include:

Note that these prices are typically out-of-pocket costs paid by the patientbecause most insurance companies will not cover them. They are considered experimental and unapproved by the FDA. This means patients needing stem cell treatment will need to use their own savings.

Although fat is a frequently utilized source for stem cells, it is also possible for physicians to utilize stem cells from bone marrow. Regenexx provides this service in the U.S. and Cayman Islands. With theRegenexxstem cell injection procedure, a small bone marrow sample is extracted through a needle, and blood is drawn from a vein in the arm. These samples are processed in a laboratory, and the cells it contains are injected into an area of the body that needs repair. On June 19, 2018, ACAP Health, a leading provider in innovative, clinical-based solutions partnered with Regenexx to reduce high-cost musculoskeletal surgeries.ACAP Health is a national leader in employer healthcare expense reduction. It is one of the first healthcare groups to partner with a stem cell treatment group to support insurance coverage to patients.

A recent Twitter poll conducted by BioInformant reported that, on average, patients can expect to spend $25,000 or more on stem cell therapies. According to the poll,

Most likely, those paying lower stem cell treatment costs under $5,000 were pursuing treatment for orthopedic or musculoskeletal conditions. In contrast, those paying higher treatment costs were likely getting treated for systemic or more complex conditions, such as diabetes, multiple sclerosis (MS), neurodegenerative diseases (such as Alzheimers disease or dementia), psoriatic arthritis, as well as the treatment for autism.

In the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes blood drawn from a patient can cost as little as $1,500. However, protocols that utilize a bone marrow or adipose (fat) tissue extraction can run as much as $15,000 $30,000. This is because bone marrow extraction is an invasive procedure that requires a penetrating bone and adipose tissue extraction requires a medical professional trained in liposuction.

For treatments that require a systemic or whole-body approach, the cost tends to be in the higher range, often averaging from $20,000 to $30,000. Examples of the diseases or conditions requiring this type of stem cell treatment include:

These higher costs reflect the complexity of treating these patients and the fact that multiple treatments are often required.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert, theStem Cell Institutein Panama is one of the worlds most trusted adult stem cell therapy centers. Over the past 12 years, the center has performed more than10,000 procedures, making it a widely recognized destination for stem cell treatments.

Working in collaboration with universities and physicians worldwide, its stem cell treatment protocols utilize combinations of allogeneic human umbilical cord blood stem cells and autologous bone marrow stem cells to treat a wide variety of conditions.

A reader of BioInformant was recently treated for psoriatic arthritis at the Stem Cell Institute in Panama in early 2018. The price of his stem cell treatment was $22,000. With travel and lodging included, the total expenses were approximately $30,000.

Because of its proximity to the U.S., Mexico is increasingly becoming a destination for medical tourism.Before choosing a stem cell treatment provider in Mexico, ensure the clinic is fully authorized by COFEPRIS, the Mexican equivalent to the FDA.

One patient who recently shared stem cell treatment quotes with BioInformant found that the treatment for glycogen storage disease, a metabolic disorder that often onsets in infancy and continues into adulthood, would cost $23,900 throughGIOSTAR Mexico.

In contrast, the patient was quoted$33,000 throughCelltex, a U.S.-based company that treats patients in Cancun, Mexico.Celltex follows FDA regulations concerning the export of cells to Mexico and is compliant with the standards and procedures of COFEPRIS. Celltex also has an alliance with a certified hospital in Mexico, which is approved to receive cells and administer them to patients by a licensed physician.

In contrast, the patient was quoted $10,000 from Stem Cell Therapy of Las Vegas and Med Spa, an American clinic. This price difference may reflect regulatory restrictions that prevent U.S. providers from expanding cells. It may also reflect the therapeutic approach used by the clinic, as well as the quality of their expertise.

In Mexico, where certain types of stem cell expansion are allowed that are restricted within the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes peripheral blood from a patient can cost as little as $1,000. In contrast, protocols that utilize more invasive sources of stem cells can run as much as $15,000 $35,000. Examples of invasive procedures includebone marrow and adipose tissue extraction. In some cases, hospitalization may be required, which raises costs. The location of a stem cell facility can factor heavily into thecost of the procedure.

Not every cost associated with treatment gets billed to the patient at the time of the procedure. Hidden costs such as reactions to the treatment, graft-versus-host disease, or disability derived from the treatment can all result in more money to the patient, to insurance, or to the government.

For example, in the case of someone with cancer, it frequently isnt viable to harvest the patients own stem cells because they may contain cancerous cells that can reintroduce tumors to the body. Instead, the patient would receive stem cells by transplant. Treatments that involve cells from another person are called allogeneic treatments. The danger here is that the body may see those cells as invaders and attack them via the immune system, a condition known as graft-versus-host disease (GvHD). The body (host) and the introduced stem cells (graft) then battle rather than coexist.

Transplanted cells often face the risk of being rejected by their host; this article discusses the effect of plasma exchange on acute graft vs. host diseasehttps://t.co/cA3nzFntew

Katie Bunde (@kbuns76) May 29, 2018

In addition to making the stem cell treatments less effective or ineffective, GvHD can be deadly. Roughly30 to 60 percent ofhematopoieticstem cell and bone marrow transplantationpatients sufferfrom it, and of those, 50 percent eventually die. The hospital costs associated with it are substantial.

Another hidden cost is the potential to disrupt a system that formerly functioned adequately. The best current example of this isthe case of Doris Tyler, who received bilateral stem cell injections in her eyes from Drs.RobertHalpernand JamieWalraven of Stem Cell Center of Georgia. According to her, while her vision was failing, it was still good enough to perform various tasks, and now it is not. That means the cost increases for her, as well as potential insurance or disability claims (though again, insurance is unlikely to cover the specific consequences of this action).

Because of tight regulations surrounding stem cell procedures performed in the United States, many stem cell treatment providers provide both on-shore (U.S.-based) and offshore (international) treatment options.Depending on where a treatment is received, patients may have to pay travel, lodging,and miscellaneous expenditures.

For example, Regenexx offers treatments at a wide range of U.S. facilities using non-expanded stem cells. However, it also offers a laboratory-expanded treatment option at a site in the Cayman Islands, which can administer higher cell doses to patients by expanding the cells in culture within a laboratory.

Similarly, Okyanos (pronounced Oh key AH nos) offers treatments to patients at its Florida location and provides more involved stem cell procedures at its offshore site inGrand Bahama. It was founded in 2011 and is a stem cell therapy provider specializing in treatments for congestive heart failure (CHF) and other chronic conditions. It is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Similarly, Celltex is headquartered in Houston, Texas, but offers stem cell treatments in Cancun, Mexico. Celltex specializes in storing a patients mesenchymal stem cells (MSCs) for therapeutic use.

While no hard evidence yet points to stem cell clinics raising their rates as a result of lawsuits, that is a typical response in industries whose products or services the public perceives as a high risk.

An additional danger to stem cell treatment providers,points out Nature, is the reduction of bottom-line profits through former patients winning suits. If clinics have to pay out the money they earned and then some to individuals suing for damages, they may soon become faced with an unviable business model. That is a definite concern for those hoping to leverage these treatments now and in the future.

As with any other area of medicine, patient evaluations of stem cell providers and treatments run the gamut from extremely satisfied to desolately unhappy. Those like Doris Tyler who have lost their eyesight exist at the negative end of the spectrum. However, many others praise stem cell treatments for their power to heal diseases, boost immunity, fight cancer, and more.

For example, BioInformants Founder and President, Cade Hildreth, had a favorable experience with stem cell therapy. Cade had bone marrow-derived stem cells collected and then had them re-injected into the knee to treat a devastating orthopedic injury. Cade was able to reverse pain, swelling, and scarring to reclaim an elite athletic ability.

As of now, this much is clear. There exists enough interest in America and across the world that stem cell providers are continuing to offer a wide range of treatments. Stem cell treatments also offer the potential to reverse diseases that traditionally had to be chronically managed by drugs. Like most medical practices, stem cell treatments will require further testing to reveal merits and faults. Until then, the public will likely continue to pursue services when medical needs arise.

Although the cost of stem cell therapy is pricey, some patients choose to undergo the treatment because it is more economical than enduring the costs associated with chronic diseases.

Although most stem cell therapy providers do not provide FDA-approved procedures, the Food and Drug Administration (FDA) continues to encouragepatients to pursue approved therapies, even if there is a higher associated treatment cost.

Providers rarely post their prices for stem cell treatments in print or digital media because they want patients to understand the benefits of therapy before making a price decision. Additionally, the price of stem cell treatments varies by condition, the number of treatments required, and the complexity of the procedure, factors that can make it difficult for medical providers to provide cost estimates without a diagnostic visit for the patient. However, in many cases, it is not in the patients best interest to make treatment decisions based on the cost of stem cell therapy. The best way to know whether to pursue stem cell therapy is to explore patient outcomes by condition and compare the healing process to other surgical and non-surgical treatment options.

The cost of stem cell therapy is indeed expensive, especially because the procedures are rarely covered by health insurance. However, with the right knowledge and a clear understanding of the treatment process, the risk of undergoing stem cell therapy can be worth it, especially if it removes the requirement for a lifetime of prescription medication. Although stem cell therapy has associated risks, it has improved thousands of lives and will continue to play in a key role in the future of modern medicine.

Download this infographic for your reference:

Are you seeking a stem cell treatment? If so, we have partnered with GIOSTAR to help you acccess medical guidance and advice.

In alignment with what we believe at BioInformant, GIOSTARs goal is to offer cutting-edge, extensively researched stem cell therapy options designed to rejuvenate and improve a patients quality of life.

Click here to Schedule a Consultation or ask GIOSTAR a question.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Do you think the cost of stem cell therapy is too much? Share your thoughts in the comments section below.

Up Next: Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research

Cost Of Stem Cell Therapy And Why Its So Expensive

Continue reading here:
The Cost Of Stem Cell Therapy And Why It's So Expensive ...

Read More...

Stem Cell Treatments and Therapies from Beike Biotechnology

Monday, February 4th, 2019

Acupuncture

Acupuncture is a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. It is one of the most effective practices used in traditional Chinese medicine. Acupuncture stimulates nerve fibers to transmit signals to the spinal cord and brain, activating the bodys central nervous system. The spinal cord and brain then release hormones responsible for making us feel less pain while improving overall health. Acupuncture may also: increase blood circulation and body temperature, affect white blood cell activity (responsible for our immune function), reduce cholesterol and triglyceride levels, and regulate blood sugar levels.

Aquatherapy

Aquatic Physical Therapy is the practice of physical therapy in a specifically designed water pool with a therapist. The unique properties of the aquatic environment enhance interventions for patients with neurological or musculoskeletal conditions. Aquatic therapy includes a wide range of techniques allowing patients to improve their balance, muscle strength and body mechanics. Aquatic therapy works to enhance the rehabilitation process and support effectiveness of stem cell treatment.

Epidural Stimulation

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the medical use of oxygen at a level higher than atmospheric pressure. The equipment required consists of pressure chamber, which may be of rigid or flexible construction, and a means of delivering 100% oxygen into the respiratory system. Published research shows that HBOT increases the lifespan of stem cells after injection and provides an oxygen-rich atmosphere for the body to function at optimum levels.

Nerve Growth Factor (NGF)

Nerve growth factor (NGF) is a member of the neurotrophic factor (neurotrophin, NTFS) family, which can prevent the death of nerve cells and has many features of typical neurotransmitter molecules. NGF plays an important role in the development and growth of nerve cells. NGF is synthesized and secreted by tissues (corneal epithelial, endothelial, and corneal stromal cells), and it can be up-taken by sympathetic or sensory nerve endings and then transported to be stored in neuronal cell bodies where it can promote the growth and differentiation of nerve cells.NGF can exert neurotrophic effects on injured nerves and promote neurogenesis (the process of generating neurons from stem cells) that is closely related to the development and functional maintenance and repair of the central nervous system. It is also capable of promoting the regeneration of injured neurons in the peripheral nervous system, improving the pathology of neurons and protecting the nerves against hypoxia (lack of oxygen)/ischemia (lack of blood supply).

Nutrition Therapy

Occupational Therapy

Occupational therapy interventions focus on adapting the environment, modifying the task and teaching the skill, in order to increase participation in and performance of daily activities, particularly those that are meaningful to the patient with physical, mental, or cognitive disorders. Our Occupational Therapists also focus much of their work on identifying and eliminating environmental barriers to independence and participation in daily activities, similar to everyday life.

Physiotherapy

Physical therapy or physiotherapy (often abbreviated to PT) is a physical medicine and rehabilitation specialty that, by using mechanical force and movements, remediates impairments and promotes mobility, function, and quality of life through examination, diagnosis, prognosis, and physical intervention. We combine our PT with stem cells for maximum physical rehabilitation improvements.

Transcranial Magnetic Stimulation

Research has shown that TMS can effectively treat symptoms of depression, anxiety, neurological pain, stroke, spinal cord injuries, autism and more. This procedure is very simple and noninvasive. During the procedure, a magnetic field generator or coil is placed near the head of the person receiving the treatment. The coil produces small electrical currents in the region of the brain just under the coil via electromagnetic induction. This electrical field causes a change in the transmembrane current of the neuron which leads to depolarization or hyperpolarization of the neuron and the firing of an action potential.

Go here to see the original:
Stem Cell Treatments and Therapies from Beike Biotechnology

Read More...

Domestic policy of the George W. Bush administration …

Monday, January 28th, 2019

This article discusses the domestic policy of the George W. Bush administration.

Following the September 11 attacks, the Bush Administration proposed and Congress approved, a series of laws stated to be necessary in prosecuting the "War on Terror." These included a wide variety of surveillance programs, some of which came under heavy fire from civil liberties interest groups that criticized the new regulations for infringing upon certain civil liberties. The administration has also been criticized for refusing to back various security measures relating to port security in 2003 and 2004 and vetoing all US$39 million for the 2002 Container Security Initiative.

In early 2001, President Bush worked with Republicans in Congress to pass legislation changing the way the federal government regulated, taxed and funded charities and non-profit initiatives run by religious organizations. Although prior to the legislation it was possible for these organizations to receive federal assistance, the new legislation removed reporting requirements, which required the organizations to separate their charitable functions from their religious functions. Bush also created the White House Office of Faith Based and Community Initiatives.[1] Days into his first term, Bush announced his commitment to channeling more federal aid to faith-based service organizations. Bush created the Office of Faith-Based and Community Initiatives to assist faith-based service organizations. Critics claimed that this was an infringement of the separation of church and state.[2][3]

As Governor of Texas, Bush had opposed efforts to repeal the criminal prohibition on "homosexual conduct", the same law that the United States Supreme Court overturned in 2003, Lawrence v. Texas. During the 2000 campaign he did not endorse a single piece of gay rights legislation, although he did meet with an approved group of Log Cabin Republicans, a first for a Republican presidential candidate.[4]

In his first four years of office, his views on gay rights were often difficult to ascertain, but many experts feel that the Bush White House wanted to avoid bad publicity without alienating evangelical conservative Christian voters. Thus, he did not repeal President Clinton's Executive Order banning discrimination based on sexual orientation in the federal civilian government, but its critics felt it was ignored.[5] He did not attempt to repeal Don't ask, don't tell, nor try to change it. He threatened to veto the Matthew Shepard Act, which would have included sexual orientation in hate crimes.

While President Bush had always been on record as opposing the legal recognition of same-sex marriages, the 2004 Republican campaign strategy was to focus on "value issues" such as a Federal Marriage Amendment, that would prohibit same-sex couples from obtaining any legal recognition. President Bush endorsed this proposed amendment, but late in the campaign told ABC News and Larry King that he did not have a problem with state legislators enacting some type of civil unions legislation, although critics charged that the constitutional amendment he endorsed did not permit recognition of such unions.

Bush still expressed support for the Federal Marriage Amendment in his February 2, 2005 State of the Union addressand during the 2006 midterm election, but given that it did not even receive majority support in the Senate, has ignored this issue in his most recent public statements and speeches.

Bush was the first Republican president to appoint an openly gay man to serve in his administration, Scott Evertz, as director of the Office of National AIDS Policy.[6] In addition, during Bush's first term, his nominee as ambassador to Romania, Michael E. Guest, became the first openly gay man to be confirmed by the Senate as a U.S. ambassador. The first openly gay ambassador, James Hormel, received a recess appointment from Bill Clinton after the Senate failed to confirm the nomination.

According to a CNN exit poll, Bush's support from African-Americans increased during his presidency from 9% of the black vote in 2000 to 11% in 2004.[7] An increase in Ohio (from 9% to 16%,[7] each about 5%) may have helped give the victory to Bush over Kerry.

Although Bush expressed appreciation for the Supreme Court's ruling upholding the selection of college applicants for purposes of diversity, his Administration filed briefs against it. Bush has said he opposes government sanctioned and enforced quotas and racial preferences, but that the private and public sector should be encouraged to reach out to accomplished minorities to increase employment diversity.

In August 2005, a report by the United States Commission on Civil Rights states that "the government fails to seriously consider race-neutral alternatives as the Constitution requires."[8] Chairman Gerald A. Reynolds explained, "Federal agencies do not independently evaluate, conduct research, collect data, or periodically review programs to determine whether race-neutral strategies will provide an adequate alternative to race-conscious programs." Civil rights groups expressed concern that the report was an attack on affirmative action inconsistent with Grutter v. Bollinger.

In his first term, Bush appointed Colin Powell as Secretary of State. Powell was the first African-American man to serve in that position, and was succeeded by Condoleezza Rice: Rice became the first African-American woman to hold the post. In 2005, he appointed Alberto Gonzales as the United States Attorney General, the first Hispanic to hold that position.

Bush met with the National Urban League, the nation's oldest civil rights organization during his term of office as well.

President George W. Bush signed into law the Genetic Information Nondiscrimination Act (GINA).[9][10] The bill protects Americans against discrimination based on their genetic information when it comes to health insurance and employment. The issue had been debated for 13 years before becoming law. It is designed to protect citizens while not hindering genetic research.

On December 19, 2002, Bush signed into law H. R. 4664, far-reaching legislation to put the National Science Foundation (NSF) on a track to double its budget over five years and to create new mathematics and science education initiatives at both the pre-college and undergraduate level.[11] In the first three years of those five, the R&D budget has increased by fourteen percent.[12][13] Bush has long been dogged by criticism that his administration ignores or suppresses scientific advice.[14] Bush showed support for oceanography and space exploration; and supported sciences on reducing pollution. Bush generally was opposed to biology especially the science of human reproduction and reproductive health; and science with global warming. Bush supported "Teach the Controversy". Bush's positions were not always shared by his party.

President Bush supported adult stem cell research and umbilical cord blood stem cell research. However, Bush opposed any new embryonic stem cell research, and had limited the federal funding of existing research. Federal funding for embryonic stem cell research was first approved under President Clinton on January 19, 1999,[citation needed] but no money was to be spent until the guidelines were published. The guidelines were released under Clinton on August 23, 2000.[citation needed] They allowed use of unused frozen embryos. On August 9, 2001, before any funding was granted under these guidelines, Bush announced modifications to the guidelines to allow use of only existing stem cell lines.[15] While Bush claimed that more than 60 embryonic stem cell lines already existed from privately funded research, scientists in 2003 said there were only 11 usable lines, and in 2005 that all lines approved for Federal funding are contaminated and unusable.[16] Adult stem cell funding was not restricted and was supported by President Bush as a more viable means of research.

On January 14, 2004, Bush announced a Vision for Space Exploration,[17] calling for the completion of the International Space Station by 2010 and the retirement of the space shuttle while developing a new spacecraft called the Crew Exploration Vehicle under the title Project Constellation. The CEV would be used to return American astronauts to the Moon by 2018, with the objective of establishing a permanent lunar base, and eventually sending future manned missions to Mars.[18] To this end, the plan proposes that NASA's budget increase by five percent every year until it is capped at US$18 billion in 2008, with only inflationary increases thereafter.[19] The planned retirement of the Space Shuttle fleet in 2010 after the ISS is completed is also expected to free up US$5 billion to US$6 billion a year. The US$16.2 billion budget for 2005 proposed by NASA met with resistance from House and Senate spending committees, and the initiative was little-mentioned during the presidential campaign.[20] Nonetheless, the budget was approved with only minor changes shortly after the November elections.

Supporters believe that this plan will be an important part of what Bush set in place while in office. However, the policy has been criticized on two fronts. Firstly, critics have opined that the United States should deal with solving domestic issues before concentrating on space exploration. Secondly, of the funding over the next five years that Bush has proposed, only US$1 billion will be in new appropriations while the remaining US$11 billion will be reallocated from NASA's other programs, and therefore inadequate to fully realize this vision. Most of the spending for the new program, and most of the budget cuts for existing programs, are scheduled after the last year of the Bush presidency. It is unclear how the space vision will be reconciled with budgetary concerns in the longer term.

In January 2005, the White House released a new Space Transportation Policy fact sheet[21] which outlined the administration's space policy in broad terms and tied the development of space transport capabilities to national security requirements.

In December 2003, Bush signed legislation implementing key provisions of his Healthy Forests Initiative. Another subject of controversy is Bush's Clear Skies Initiative, which seeks to reduce air pollution through expansion of emissions trading.

Bush signed the Great Lakes Legacy Act of 2002 authorizing the federal government to begin cleaning up pollution and contaminated sediment in the Great Lakes, as well as the Brownfields Legislation in 2002, accelerating the cleanup of abandoned industrial sites, or brownfields, to better protect public health, create jobs, and revitalize communities.

Bush stated his reason for not supporting the Kyoto Protocol was that it unfairly targeted the United States while being deliberately lenient with certain developing countries, especially China and India. Bush stated, "The world's second-largest emitter of greenhouse gases is China. Yet, China was entirely exempted from the requirements of the Kyoto Protocol."

Bush also questioned the science behind the global warming phenomenon, insisting that more research be done to determine its validity.[22]

Upon arriving in office in 2001, President Bush withdrew United States support of the then-pending Kyoto Protocol, a UN Convention seeking to impose mandatory targets for reducing "greenhouse gas" emissions. Bush stated that human activity had not been proven to be the cause and cited concerns about the treaty's impact on the U.S. economy and pointed out that China and India had not signed on.[23] The Protocol entered into force on 16 February 2005. As of September 2011, 191 states have signed and ratified the protocol.[24] The only remaining signatory not to have ratified the protocol is the United States.

In 2002, the Bush Administration's EPA issued a Climate Action Report concluding that the climate changes observed over several decades "are likely mostly due to human activities, but we cannot rule out that some significant part of these changes is also a reflection of natural variability".[25] While the EPA report was initially hailed by some environmentalists critical of the Bush administration as a "180-degree turn on the science" reversing "everything the president has said about global warming since he took office," within days President Bush dismissed the report as being "put out by the bureaucracy," and reaffirmed his opposition to the Kyoto Protocol.[25]

The Bush Administration's stance on global warming, and in particular its questioning the consensus of scientists, would remain controversial in the scientific and environmental communities during his presidency. In 2004, the Director of NASA's Goddard Institute, James E. Hansen, came out publicly and harshly accusing the Administration of misinforming the public by suppressing the scientific evidence of the dangers of greenhouse gases, saying the Bush Administration wanted to hear only scientific results that "fit predetermined, inflexible positions" and edited reports to make the dangers sound less threatening in what he asserted was "direct opposition to the most fundamental precepts of science."[26][27] Other experts, such as former U.S. Department of Energy official Joseph Romm, have decried the Bush administration as a "denier and delayer" of government action essential to reduce carbon emissions and deter global warming.[28]

In 2005, Council on Environmental Quality chairman and former oil industry lobbyist Philip Cooney, was accused of doctoring and watering down descriptions of climate research from other government agencies. The White House denied these reports.[29] Two days later, Cooney announced his resignation[30] and conceded his role in altering the reports. "My sole loyalty was to the President and advancing the policies of his administration," he told the United States House Committee on Oversight and Government Reform.[31][32]

In addition, the administration thanked Exxon executives for the company's "active involvement" in helping to determine climate change policy, including the US stance on Kyoto.[33]

President Bush believes that global warming is real[34] and has said that he has consistently noted that global warming is a serious problem but asserted there is a "debate over whether it's manmade or naturally caused" and maintained that regardless of that debate his administration was working on plans to make America less dependent on foreign oil "for economic and national security reasons."[35]

The United States has signed the Asia Pacific Partnership on Clean Development and Climate, a pact that allows signatory countries to set goals for reducing greenhouse gas emissions individually, but with no enforcement mechanism. Republican Governor Arnold Schwarzenegger, along with 187 mayors from US towns and cities, have pledged to adopt Kyoto style legal limits on greenhouse gas emissions.[36]

For economic and national security reasons, Bush supported Alaska Senator Ted Stevens' plan to tap the oil reserves in a 2,000-acre (8km2) area of Alaska's 19 million acre (77,000km) Arctic National Wildlife Refuge. Pro-exploration supporters argue that U.S. companies have the most stringent environmental requirements, and that by doing the drilling in the middle of the winter, it would create a very small environmental footprint.[37]

Opponents stated that drilling would damage the coastal plain's fragile ecosystem and its wildlife. Proponents stated that modern techniques can extract the oil without damaging the environment [38]

Initially announced by President Bush in 2002,[39] the Clear Skies Initiative was aimed at amending the Clean Air Act to further reduce air pollution and expanded the emissions trading programs to include new pollutants such as mercury. The goal of the initiative was to reduce the sulfur dioxide, nitrogen oxide, and mercury emissions of power plants over the course of 15 years, while saving consumers millions of dollars.[39]

Among other things, the Clear Skies Act states that it would:[40][41][42]

The Natural Resources Defense Council, and its more than 500,000 members, examined the administration proposal and concluded it would harm public health, weaken current pollution fighting programs and worsen global warming. S. 385, the administration's bill to amend the Clean Air Act would:1. Allow power plant pollution to continue to inflict huge, avoidable health damages on the public. 2. Repeal or interfere with major health and air quality safeguards in current law. 3. Worsen global warming by ignoring CO2 emissions from the power sector.[43]

In January 2002, Bush signed the No Child Left Behind Act, with Democratic Senator Ted Kennedy as chief sponsor,[44] which aims to close the achievement gap, measures student performance, provides options to parents with children in low-performing schools, and targets more federal funding to low-income schools. Critics, including Senator John Kerry and the National Education Association, say schools were not given the resources to help meet new standards, although their argument is based on premise that authorization levels are spending promises instead of spending caps. The House Committee on Education and the Workforce said that the Department of Education's overall funding increased by US$14 billion since the enactment of NCLB in fiscal year 2001, going from US$42.6 billion to US$56.6 billion in fiscal year 2005.[citation needed] Some state governments are refusing to implement provisions of the act as long as they are not adequately funded.[45]

In January 2005, USA Today reported that the United States Department of Education had paid US$240,000 to African-American conservative political commentator Armstrong Williams "to promote the law on his nationally syndicated television show and to urge other black journalist to do the same."[46] Williams did not disclose the payments.

The House Education and Workforce Committee stated, "As a result of the No Child Left Behind Act, signed by Bush on January 8, 2002, the Federal government today is spending more money on elementary and High School (K-12) education than at any other time in the history of the United States.[citation needed] Funding increases have to a large degree been offset at the state level by increased costs associated with implementing NCLB, as well as the impacts of the economic downturn on education budgets.

According to the National Bureau of Economic Research, the economy suffered from a recession that lasted from March 2001 to November 2001. During the Bush Administration, Real GDP has grown at an average annual rate of 2.5%.[47]

Inflation under Bush has remained near historic lows at about 2-3% per year. The recession and a drop in some prices led to concern about deflation from mid-2001 to late 2003. More recently, high oil prices have caused concern about increasing inflation.

Long-term problems include inadequate investment in economic infrastructure, rapidly rising medical and pension costs of an aging population, sizable trade and budget deficits. Under the Bush administration, productivity has grown by an average of 3.76% per year, the highest such average in ten years.[48]

While the GDP recovered from a recession that some claim Bush inherited from the previous administration,[49] poverty has since worsened according to the Census Bureau. The percentage of the population below the poverty level increased in each of Bush's first four years, while it decreased for each of the prior seven years to an 11-year low. Although the poverty level increased the increase was still lower from 2000 to 2002 than it was from 1992 to 1997, which reached a peak of 39.3% in 1993. In 2002 the poverty rate was 34.6% which was almost equal to the rate in 1998, which was 34.5%. Poverty was at 12.7% in 2004.[citation needed]

President Bush won passage for two major tax cuts during his term in office: The Economic Growth and Tax Relief Reconciliation Act of 2001 and the Jobs and Growth Tax Relief Reconciliation Act of 2003. Collectively, they became known, analyzed, and debated as the "Bush tax cuts".

The cuts, scheduled to expire a decade after passage, increased the standard income tax deduction for married couples, eliminated the estate tax, and reduced marginal tax rates. Bush asked Congress to make the tax cuts permanent, but others wanted the cuts to be wholly or partially repealed even before their scheduled expiration, seeing the decrease in revenue while increasing spending as fiscally irresponsible.

Bush's supporters claim that the tax cuts increase the pace of economic recovery and job creation. They also claim that total benefits to wealthier individuals are a reflection of higher taxes paid. Individual income tax rate provisions in the 2001 law, for instance, created larger marginal tax rate decreases for people earning less than US$12,000 than any other earners.[50]

His opponents contest job prediction claims, primarily noting that the increase in job creation predicted by Bush's plan failed to materialize. They instead allege that the purpose of the tax cuts was intended to favor the wealthy and special interests, as the majority of benefit from the tax cut, in absolute terms, went to earners in the higher tax brackets. Bush's opponents additionally claim that the tax cuts are a major reason Bush reversed a national surplus into a historically large deficit.

In an open letter to Bush in 2004, more than 100 professors of business and economics at U.S. business schools ascribed this "fiscal reversal" to Bush's "policy of slashing taxes - primarily for those at the upper reaches of the income distribution."[51]

By 2004, these cuts had reduced federal tax revenues, as a percentage of the Gross Domestic Product, to the lowest level since 1959. With the NASDAQ crash and one quarter of negative growth in 2000 it was likely we were headed into a recession,[52] yet merely two years after the 2003 Bush tax cuts, federal revenues (in dollars) had reached a record high.[53] The effect of simultaneous record increases in spending and tax reductions was to create record budget deficits in absolute terms, though as recently as 1993, the deficit was slightly larger than the current 3.6% of the GDP. In the last year of the Clinton administration, the federal budget showed an annual surplus of more than US$230 billion.[54] Under Bush, the government returned to deficit spending. The annual deficit reached an absolute record of US$374 billion in 2003 and then a further record of $413 billion in 2004.[55][56]

President Bush expanded public spending by 70 percent, more than double the increase under President Clinton. Bush was the first president in 176 years to continue an entire term without vetoing any legislation.[57]

The tax cuts, recession, and increases in outlays all contributed to record budget deficits during the Bush administration. The annual deficit reached record current-dollar levels of US$374 billion in 2003 and US$413 billion in 2004. National debt, the cumulative total of yearly deficits, rose from US$5.7 trillion (58% of GDP) to US$8.3 trillion (67% of GDP) under Bush,[citation needed] as compared to the US$2.7 trillion total debt owed when Ronald Reagan left office, which was 52% of the GDP.[58]

According to the "baseline" forecast of federal revenue and spending by the Congressional Budget Office (in its January 2005 Baseline Budget Projections),[59] the budget deficits will decrease over the next several years. In this projection the deficit will fall to US$368 billion in 2005, US$261 billion in 2007, and US$207 billion in 2009, with a small surplus by 2012. The CBO noted, however, that this projection "omits a significant amount of spending that will occur this year and possibly for some time to come for U.S. military operations in Iraq and Afghanistan and for other activities related to the global War on Terrorism." The projection also assumes that the Bush tax cuts "will expire as scheduled on December 31, 2010." If, as Bush has urged, the tax cuts were to be extended, then "the budget outlook for 2015 would change from a surplus of US$141 billion to a deficit of US$282 billion." Other economists have disputed this, arguing that the CBO does not use dynamic scoring, to take into account what effect tax cuts would have on the economy.

Federal spending in constant dollars increased under Bush by 26% in his first four and a half years. Non-defense spending increased 18% in that time.[60] Of the US$2.4 trillion budgeted for 2005, about US$450 billion are planned to be spent on defense. This level is generally comparable to the defense spending during the cold war.[citation needed] Congress approved US$87 billion for Iraq and Afghanistan in November, and had approved an earlier US$79 billion package last spring. Most of those funds were for U.S. military operations in the two countries.

Former President Clinton's last budget featured an increase of 16% on domestic non security discretionary spending. Growth under President Bush was cut to 6.2% in his first budget, 5.5% in his second, 4.3% in his third, and 2.2% in his fourth.

Bush supports free trade policies and legislation but has resorted to protectionist policies on occasion. Tariffs on imported steel imposed by the White House in March 2002 were lifted after the World Trade Organization ruled them illegal. Bush explained that the safeguard measures had "achieved their purpose", and "as a result of changed economic circumstances", it was time to lift them.[61]

President Bush signed a large number of free trade agreements into law during his Presidency: Jordan (2001), Singapore and Chile (2004), Australia (2005), Dominican Republic, CAFTA, Morocco, Oman, and Bahrain (2006), and Oman and Peru (2009).

The Bush administration also launched trade negotiations with New Zealand, Thailand, Kuwait, Malaysia, Qatar, South Korea, Colombia, and Panama, with some being completed during President Obama's first term in office (2009-2013).

Some say economic regulation expanded rapidly during the Bush administration. President Bush is described by these observers as the biggest regulator since President Richard Nixon.[62] Bush administration increased the number of new pages in the Federal Registry, a proxy for economic regulation, from 64,438 new pages in 2001 to 78,090 in new pages in 2007, a record amount of regulation.[62] Economically significant regulations, defined as regulations which cost more than $100 million a year, increased by 70%.[62]

Spending on regulation increased by 62% from $26.4 billion to $42.7 billion.[62]

The contrary view on Bush's regulatory record is that he discouraged regulators from enforcing regulations and that counting pages in the Federal Register is a myopic method of measuring an administration's regulatory stance. The 2008 financial crisis occurred near the end of the Bush second term and represented an enormous failure for financial deregulation.[63]

Looking at the annual average unemployment rates for each of the eight years of Bush's presidency, the average of all eight figures, and thus of his entire presidency, is 5.26%, with a low of 4.6% for the years of 2006 and 2007, and a high of 6.0% for 2003.[64]

According to the Bureau of Labor Statistics, the number of unemployed was nearly 6.0 million in January 2001 and 6.9 million in September 2006. The unemployment rate was 4.2% in January 2001, 4.6% in September 2006, and 7.2% in December 2008. Employment peaked in late 1999 and declined through 2008.[65]

The Current Population Survey (aka Household Survey) measures the percentage of the population that is employed and unemployed. The result can be multiplied by population estimates to get total employment estimates. This survey has the advantage over the payroll survey in that it includes self-employed. The Household Survey is less accurate in producing total numbers since it requires population estimates and in that it samples many fewer people (60,000 households versus 400,000 business establishments). For better or worse, the Household Survey counts multiple jobs held by one person only once, and it includes government workers, farm workers, unpaid family workers, and workers absent without pay. The Household Survey indicates that the percentage of the population employed decreased from 64.4% in December 2000 and January 2001 to 62.1% in August and September 2003. By August 2005, it had recovered only to 62.9%. In absolute numbers, this corresponds to a drop of 1.6 million jobs but an eventual net gain of 4.7 million jobs during the Bush administration.[66]Private sector employment, as measured by private nonfarm payrolls, shrank over the 8 years of the George W. Bush presidency. There were modest gains in private-sector payroll employment during his first term, but these were more than offset by the shedding of workers by the private sector in his second term. There were 463,000 fewer private-sector payroll jobs when he left office than when he came into office.[67]

In 2004, a full chapter on Iraq's economy was excised from the Economic Report of the President, in part because it doesn't fit the "feel good" tone of the writing, according to White House officials.[citation needed]

In July 2002, Bush cut off U.S. funding to the United Nations Population Fund (UNFPA). Bush stated that the UNFPA supported forced abortions and sterilizations in the People's Republic of China.[68]

Bush signed the Medicare Act of 2003, which added prescription drug coverage to Medicare (United States), subsidized pharmaceutical corporations, and prohibited the Federal government from negotiating discounts with drug companies.

Bush signed the Partial-Birth Abortion Ban Act in 2003, having declared his aim to "promote a culture of life".

Bush is an advocate of the partial privatization of Social Security wherein an individual would be free to invest a portion of his Social Security taxes in personal retirement accounts.

Bush has called for major changes in Social Security, identifying the system's projected insolvency as a priority early in his second term. From January through April 2005, he toured the country, stopping in over 50 cities across the nation warning of an impending "crisis". Initially, President Bush emphasized his proposal for personalized accounts would allow individual workers to invest a portion of their Social Security Tax (FICA) into secured investments. The main advantage of personal accounts within Social Security is to allow workers to own the money they place into retirement that cannot be taken away by political whims.

Most Democrats and some Republicans are critical of such ideas, partly because of the large (US$1 trillion or more) federal borrowing the plan would require, which might actually worsen the imbalance between revenues and expenses that Bush pointed to as a looming problem; and partly because of the problems encountered by the United Kingdom's privatized pension plan. See Social Security debate (United States). In addition, many Democrats opposed changes that they felt were turning Social Security into a welfare program that would be politically vulnerable. Portions of Bush's bill exempting private companies from social security payments have led to complaints that Bush's plan was created to benefit private companies, and that it would turn Social Security into just another insurance program.

George W. Bush is a strong supporter of capital punishment. During his tenure as Governor of Texas, 152 people were executed in that state, maintaining its record as the leading state in executions.[69] As President of the United States, he has continued in his support for capital punishment, including presiding over the first federal execution in decades, that of convicted terrorist Timothy McVeigh. Although Bush's support of the death penalty is known, controversy broke in 1999 when journalist Tucker Carlson revealed that the Governor had mocked the plight of Karla Faye Tucker in an interview.

On his first day in office, President Bush implemented the Mexico City Policy; this policy required nongovernmental organizations receiving federal funds to agree not to perform abortions or to actively promote abortion as a method of family planning in other nations.[70][71] In 2002, President Bush signed the Born-Alive Infants Protection Act, which extends legal protection to infants born alive after failed attempts at induced abortion.[72] Also in 2002, President Bush withdrew funding from the United Nations Population Fund based on a finding that UNPF's activities facilitated China's one-child-only/forced abortion policy.[73] In 2003, President Bush signed the Partial Birth Abortion Ban Act into law;[74] that law was later upheld by the Supreme Court of the United States in Gonzales v. Carhart.[75] President Bush signed the Unborn Victims of Violence Act (Laci and Conner's Law), which provides that a person who commits certain federal violent crimes and thereby causes the death of, or bodily injury to, a fetus shall be guilty of a separate offense, whether or not the person knew the mother was pregnant or intended to harm the fetus.[76]

Bush staunchly opposes euthanasia. He supported Ashcroft's decision to file suit against the voter-approved Oregon Death with Dignity Act, which was ultimately decided by the Supreme Court in favor of the Oregon law.[77] As governor of Texas, however, Bush had signed a law which gave hospitals the authority to take terminally ill patients off of life support against the wishes of their spouse or parents, if the doctors deemed it medically appropriate.[78] This became an issue in 2005, when the President signed controversial legislation forwarded and voted on by only three members of the Senate to initiate federal intervention in the Terri Schiavo case.[79]

Bush signed the Amber Alert legislation into law on April 30, 2003, which was developed to quickly alert the general public about child abductions using various media sources.[80] On July 27, 2006 Bush signed the Adam Walsh Child Protection and Safety Act which establishes a national database requiring all convicted sex offenders to register their current residency and related details on a monthly instead of the previous yearly basis. Newly convicted sex offenders will also face longer mandatory incarceration periods.[81]

On June 15, 2006, Bush created the seventy-fifth, and largest, National Monument in U.S. history and the largest Marine Protected Area in the world with the formation of the Northwestern Hawaiian Islands National Monument.[82]

The Prison Rape Elimination Act of 2003 (PREA) is the first United States federal law passed dealing with the sexual assault of prisoners. The bill was signed into law on September 4, 2003. As a result, the National Prison Rape Elimination Commission was created to study the problem and recommend solutions. Federal funding for prisons also began to require detainment facilities to keep records on sexual assault. Failure to follow PREA requirements resulted in losing up to 5% of funding. New grants to prevent sexual assault were also created by the law. Significant support for the act came from Human Rights Watch, Concerned Women for America, Just Detention International, and numerous evangelical organizations.

In 2005-06, Bush emphasized the need for comprehensive energy reform and proposed increased funding for research and development of renewable sources of energy such as hydrogen power, nuclear power, ethanol, and clean coal technologies. Bush proposed the American Competitiveness Initiative which seeks to support increasing competitiveness of the U.S. economy, with greater development of advanced technologies, as well as greater education and support for American students. In the 2007 State of the Union speech, President Bush proposed a 20:10 policy, where, as a nation, the United States would be working to reduce 20% of the national energy usage in next 10 years by converting to ethanol.

Bush's imposition of a tariff on imported steel and on Canadian softwood lumber was controversial in light of his advocacy of free market policies in other areas. The steel tariff was later rescinded under pressure from the World Trade Organization. A negotiated settlement to the softwood lumber dispute was reached in April 2006, and the historic seven-year deal was finalized on July 1, 2006.[citation needed]

Go here to see the original:
Domestic policy of the George W. Bush administration ...

Read More...

Neil Riordan PhD – Medistem Panama

Sunday, January 13th, 2019

Neil Riordan, PhD is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPIs stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordans research team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.

Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis, Duchenne Muscular Dystrophy, Autism, and Charcot Marie Tooth Syndrome. In 2007, Dr. Riordans research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the Medical Article of the Year Award from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the America

Continued here:
Neil Riordan PhD - Medistem Panama

Read More...

Nobel Prize Doctor Yamanaka: Stem Cell Progress ‘Just the …

Saturday, November 17th, 2018

Professor Shinya Yamanaka of Kyoto University, 55, became more widely known after he was awarded the Nobel Prize in Physiology or Medicine in 2012. Five years before that, however, in November 2007, he announced that he had generated human-induced pluripotent stem cells (iPS cells).

His research on treating illnesses has seen impressive progress, but, according to him, this is just the beginning.

Yamanaka, 55, was born in 1962 in Osaka. He graduated from Kobe University School of Medicine and completed his PhD at Osaka University Graduate School. He became a professor at Kyoto University in 2004 and the director of Center for iPS Cell Research and Application in 2010.

He recently spoke with journalist Juichiro Ito of Sankei Shimbuns Science Department about the future of medical treatment through iPS cell generation.

Its the 10th anniversary of human iPS cell generation.

It sounds like a long time, but it feels like yesterday. I cant believe it has been that long. Maybe time flies faster for me because Im old now, but this is only the beginning.

Research on regenerative medicine and clinical trials of new drugs have begun.

iPS cells have been a catalyst to research that use embryonic stem cells (ES cells). I cannot take all the credit because I wouldnt have made it this far without the efforts of everyone involved. I always remind myself how grateful I should be. Clinical research on age-related macular degeneration (AMD) led by Masayo Takahashi of Riken research institute impressed me the most. By skipping the preclinical development stage consisting of animal testing, she managed to make significant accomplishments in a very short period.

What was the challenge?

The challenge was to build an iPS cell stock which ensures that iPS cells will always be available for regenerative medicine and drug discovery. The process involves providing cells to a specialized company for mass production, which then supplies the cells to medical institutes and pharmaceutical companies. It was a very difficult process because university researchers are a type of people who want to challenge themselves with the unprecedented. Conversely, the production of cells requires the dull repetition of prescribed steps in order to maintain quality. Dealing with this contrast was very difficult.

At first, people pointed out the risks of the cells becoming cancerous.

The early-stage iPS cells couldnt be used for clinical research because of these concerns. However, the production method has evolved and the situation has changed. The risk has not been completely eliminated but is significantly lower, so the cells can now be used for clinical research.

You were awarded the Nobel Prize in Physiology or Medicine in 2012.

It was a great honor. The moment I successfully generated iPS cells, I had the huge responsibility of getting things off the ground, starting with the clinical research. But receiving the prize increased awareness within the general public and those in the industry, and this became a tailwind for my research in many ways. Im very grateful for that, as it also helped Kyoto University collect funds for the Center for iPS Cell Research Application (CiRA).

If you were to compare the current iPS research to a marathon, how many kilometers do you still have to run?

It might be an exaggeration to say that were only at the start line, but I would say weve run no more than 10 kilometers. The real challengethe crucial stagesstarts now, including clinical research and trials of new drugs. Our goal is truly ambitious, as we are taking unprecedented steps while prioritizing the safety of the patients. Im assuming that the challenges that lie ahead will be incomparable to anything Ive faced in the past.

What is the goal of the research?

I estimate that several treatments using regenerative medicine and new drugs will be developed, authorized, and covered by insurance around 2030. However, some treatments may take longer to develop, and unforeseeable challenges may come up. We cannot simply visualize our goal. Its more important to take slow but sure steps towards it.

What are the problems regarding cost and time?

In regenerative medicine, it takes a lot of money and time to custom-make iPS cells from the patients cells. Instead, we create iPS cells from dozens of people with an immunological type that has a lower risk of rejection in Japanese people. However, the great hurdle is how to maintain ample stock of these cells.

What percentage of the population do the cells cover?

Currently, we provide iPS cells of three immunological types. They will not trigger a rejection response in 30% of the Japanese population. It shouldnt be long until we reach 50%. However, we are concerned that increasing the types of iPS cells available will inevitably lead to a higher production cost, which means the cells might become difficult to access for medical treatment. The more cell types there are, the more production facilities the manufacturing companies will require, and more money and time will be necessary for safety checks. Alternatively, it might be more efficient to use just one type of cell which covers the greatest percentage of the population, and to provide immunosuppressant drugs to those that have a rejection response.

What is your plan for the future?

If a huge amount of national expenditure is invested into creating more types of cells but the cells end up being unusable, it would be a considerable waste. Until now, we have been aiming to reach 80% of the population by 2022, but we are now reevaluating our goal. This is a problem we cannot solve by ourselves. We want the government to consider implementing a system that ensures safety checks while containing the costs.

Clinical research and trials have started to make the cells useful for patients.

We have only just reached the start line. For the next 10 or 20 years, it will be more like the patients contributing to the research at their own risk, rather than us contributing to them. I need to start making true contributions to the patients as soon as possible. People enduring incurable diseases have written numerous letters to us about their wish to be cured using iPS cells. I am fully aware of their desperate situation and working hard towards making their wish come true.

Ikumi Yamamoto, 19, from Akashi in Hyogo Prefecture, who suffered from fibrodysplasia ossificans progressiva (FOP), underwent the first ever treatment for incurable diseases using iPS cells in October.

She came to see me when she was a sixth grade elementary student, and told me that she wanted me to generate iPS cells using her cells to further my research. Such encounters have become a driving force in my research. I think of iPS cells as the patients themselves. When I conduct experiments, the face of the patients who provided the original cells always come to my mind, which makes me more determined to find a cure for them.

Hideo Shinozawa, an honorary professor of Gakushuin University, died in October after a long battle with amyotrophic lateral sclerosis (ALS).

The professor sent me a letter to tell me how much he wanted me to develop a treatment. The letter is displayed in my laboratory so that I am always reminded of his strong desire while I go about my work. ALS is one of the diseases I want to defeat the most. I want to find a cure as soon as possible, but Im unfortunately not at that stage yet.

What kind of attitude should medical researchers have?

As a researcher, you must first conduct good research and write research papers. While doing this, the researcher must have a strong determination to help the patients no matter how long it takes. Being a researcher is difficult, but thinking about the patients keeps us going.

Do you still run marathons as a hobby?

During my lunch breaks on weekdays, I run for 30 minutes along Kamo River and near Nanzen-ji Temple, which are located near the research institute. On weekends, I run around Osaka Castle near my house and around the Tokyo Imperial Palace when Im in Tokyo for work. Running helps me refresh my tired brain, just like the initialization process involved in iPS cell generation.

I managed to run a personal best of 3 hours 27 minutes and 42 seconds at the Kyoto Marathon in February. I will run the Osaka Marathon in November. The Beppu-ita Marathon, which I will be running next February, will be used to select representatives for the 2020 Tokyo Olympics, so I might have a chance. Perhaps well see a miracle (laughs).

The Rapid Progress of Clinical Research and the Challenge of Efficient Cell Generation

iPS cell research has garnered attention as people put their hopes on regenerative medicine to transplant new cells and tissue to injured or ill patients. Research institute Riken succeeded in the first ever transplant in 2014 using iPS cells, setting a major landmark in this field.

The transplant involved creating retinal cells using iPS cells generated from a patient with age-related macular degeneration, a serious eye condition. In March 2017, the transplant of retinal cells from a donor using stock iPS cells succeeded, totalling five successful transplants.

For 2018, clinical research on spinal cord injury and heart failure are being scheduled by Keio University and Osaka University, respectively. Yokohama City University also plans to conduct clinical research on liver failure in 2019 onwards, making Japan the trail blazer in this area. However, most of this research is on cell transplantation; the possibility of transplanting complex organs is still not within reach.

iPS cells are also used to research the pathogenesis of diseases and drug discovery. This is because the mechanisms of diseases can be revealed by creating iPS cells from patients with incurable diseases and replicating the disease outside of the body. Recently, the mechanisms of diseases that affect the motor system, such as Parkinsons disease and ALS, have become better understood.

The mass production of the patients cells for testing makes the development of new drugs more efficient. Potential treatment for FOP, a disease that turns muscle into bone, has been discovered through this method. The method is also being used for ALS and Alzheimers disease. However, this method has not met early expectations that it would be available for clinical application sooner than regenerative medicine.

The big challenge is efficient cell generation. It takes several months to create iPS cells and cells of the affected area. Research on implementing artificial intelligence for efficiency and improvement of cell generation methods is intensifying.

Juichiro Ito is a staff writer of the Sankei Shimbun Science news department.

See the rest here:
Nobel Prize Doctor Yamanaka: Stem Cell Progress 'Just the ...

Read More...

Crowdfunding to have an advanced Stem cell treatment in …

Thursday, October 18th, 2018

Thank you for opening my page. I am 34 years old and can only travel short distances with a walking stick due to my worsening condition. MS is caused by the immune system attacking the nervous system and causes many dibilitating symptoms. I am desperately raising money for this treatment to halt and repair the damage so I can lead a normal life and start to plan for my future.....please take a moment to hear my story.

Throughout 2013 I had many visits to my Doctors to discuss my worsening symptoms that were causing concern. On every occasion I visited the GP I was dismissed and misdiagnosed. In February 2014 I collapsed and was immediately rushed to hospital, as I could not see or walk. My girlfriend and I who had only been together weeks had our dreams shattered, we knew things were going to get tough but this has been gruelling. I have had to relearn to walk and I have never fully regained my vision.

Four years since my diagnosis and it is like living a nightmare. My symptoms have grown significantly worse, medication available on the NHS, changes to my diet, holistic treatments and supplements have made little difference. My symptoms have meant that I have been forced to reduce my working hours and I am increasingly house-bound. There is currently no cure for this on the NHS. There are successful trials being undertaken by Cambridge University but with the speed and the progression of my illness I dont have the time to wait before my condition worsens. This is why I am asking for your help, even the smallest of donations will go a very long way. I am totally grateful to my family and friends who are all undertaking fund raising events on my behalf. The fight is hard but I will not be defeated. I will be eternally thankful for any time, effort and money put towards this cause. This treatment could make such an improvement to my life.

Any money raised over my target will be donated to similar causes. Thanks again for reading.

Liam x

Link:
Crowdfunding to have an advanced Stem cell treatment in ...

Read More...

Stem Cell Institute – Panama – Inspire

Saturday, August 18th, 2018

Stem cell transplant and stem cell treatment are nothing alike.A HSCT wipes out the old bone marrow and replaces it with a new one. Auto=patients own stem cells, Allo= a donor's. Also, mesenchymal stem cells and hematopoietic stem cells are different. Mesenchymal stem cells do have successfully immunomodulatory effect in GVHD, for example. The donor is the same donor who donated for the HSCT. There was a phase I or II trial in the UK using the patient's own mesenchymal stem cells as pure IV with no other therapies. I need to follow-up on their results, but given that there are no further trials, I presume this was unsuccessful. It's true that the umbilical stem cells have high hopes. It is also true that selling cells or organs is illegal in the US. This would be one argument for the use in Panama but not in the US. On the other hand, this will not be a cure. It could, potentially, exert a temporary effect or perhaps some effect after SEVERAL treatments. But it isn't a cure. Also, a 'universal cure' makes it sound fishy.Having said that about Panama, there is legitimacy in HSCT, with success. This is a treatment in clinical trials. It was done in the US and Canada for SPS. Now there is a trial going on in the Philippines. It's listed on clinicaltrials.gov

See the article here:
Stem Cell Institute - Panama - Inspire

Read More...

My experience with stem cells therapy in Panama – MSWorld

Wednesday, July 18th, 2018

I'm 51, and I've multiple sclerosis since 18 years.The desease has not been too agressive in the first 14 years, but it has worsened in the last 4 years. It is secondary progressive form. My main symptoms are bladder and bowel difficulties, as well as erection problems, and to a lesser extend fatigue and spasticity in the legs.I've never had any medical treatment, as my neurologist says it doesn't work with secondary progressive MS. I'm just careful with what I eat : no animal fat, first pressure oils, organic fruits and vegetables. I'm also having various food supplements such as primerose oil, selenium, and stemenhance.

I went to the Stem Cell Institute in Panama (cellmedicine.com/locations.asp) in march 2010 for a two week treatment. I decided to tell the story of my experience on this forum, specially for those who are considering going for such therapy.

The people at the SCI were nice, friendly, and professional. Everything was well organised, with a taxi picking me up at my hotel always right on time.The different places where the treatment took place were very clean.I've had 5 intracathetal injections, and 2 intraveinous injections.The intracathetal used cells from umbilical cords, while the intraveinous were using stem cells from my own fat (obtained from a mini-liposuction).The treatment was not painful, except for the mini-liposuction which was a littleunpleasant.The treatment costed me 22500 US$. With the travel (from France) and accomodation expenses for me and the accompanying person, the total amount was approximately 26000 US$.

Unfortunately, 6 months after the treatment, I still don't feel any improvement.(but the treatment has not worsened my condition either).

Of course this is only my own experience, and others probably have indeed been improved.Now I'm just hoping that the new theory on CCSVI will eventually be the solution ...

Good luck to all of you who are in the same quest as I am.Zaz

See the rest here:
My experience with stem cells therapy in Panama - MSWorld

Read More...

Journal of Stem Cell Research and Therapy – Open Access …

Sunday, July 15th, 2018

PUBMED NLM ID: 101586297 | Index Copernicus Value: 84.95 The Journal of Stem Cell Research & Therapy is an open access journal that showcases seminal research in the field of stem cell therapy. As stem-cells are flag-bearers of translational research, the field has an interdisciplinary feel by including oncology, clinical research, medicine and healthcare under the aegis of stem-cell therapy. It also includes scientific research related to the auxiliary areas of Biology by prioritizing scholarly communication milieu and transfers expert knowledge synthesized from the ever burgeoning stem-cell literature. In order to create such impactful content, the Journal of Stem Cell Research & Therapy brings together an expert Editorial Board, which comprises of noted scholars in the field of Cell Biology. Every single article is subjected to rigorous peer review by illustrious scientists. In addition to Research Articles, the Journal also publishes high quality Commentaries, Reviews, and Perspectives aimed at synthesizing the latest developments in the field, and putting forward new theories in order to provoke debates amongst the scholars in the field. The journal thus maintains the highest standards in terms of quality and comprehensive in its approach.The journal aims to provide the authors with an efficient and courteous editorial platform. The authors can be assured of an expeditious publishing process. In this regard, the journal also provides advance online posting of the accepted articles. The Journal of Stem Cell Research & Therapy ensures barrier-free, open access distribution of its content online and thus, helps in improving the citations for authors and attaining a good impact factor.

Scholarly Journal of Stem Cell Research & Therapy is using online manuscript submission, review and tracking systems of Editorial Manager for quality and quick review processing. Review processing is performed by the editorial board members of Journal of Stem Cell Research and Therapy or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript.

It is an undifferentiated cell which is capable of transforming into more cells of same type or multiple other types. They are found in multicellular organisms. They can differentiate into cells of blood, skin, heart, muscles, brain etc. In adult human being, they replenish the dead cells of various organs. Stem cells are being used for treatment of various diseases like diabetes, arthritis, few cancers, bone marrow failure etc.

Related Journals of Stem Cell

Insights in Stem Cells, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology,Stem Cells, Cell Stem Cell, Stem Cells and Development, Stem Cell Reviews and Reports, Current Stem Cell Research and Therapy, Stem Cell Research

They can develop into any cell type or organ in the body. A single totipotent stem cell can give rise to an entire organism. Fertilized egg or a zygote is the best example. Zygote divides and produces more totipotent cells. After 4 days the cells lose totipotency and become pluripotent.

Related Journals ofTotipotent Stem Cells

Breast Cancer: Current Research, Cancer Diagnosis, Reproductive Medicine, Genetics & Stem Cell Biology, Stem Cell Research and Therapy, Stem Cells International, Stem cells translational medicine, Current Protocols in Stem Cell Biology

They can differentiate into any cell type in the human body. Embryonic stem cells are mostly pluripotent stem cells. They have the ability to differentiate into any of three germ layers: endoderm, mesoderm, or ectoderm.

Related Journals ofPluripotent Stem Cells

Cancer Science & Therapy, Cervical Cancer: Open Access, Reproductive Medicine, Genetics & Stem Cell Biology, Stem Cell Reports, Hematology/ Oncology and Stem Cell Therapy, Journal of Stem Cells, International Journal of Stem Cells

These are multipotent stem cells normally found in the bone marrow and are derived from mesenchyme. They differentiate into adipocytes, chondrocytes, osteoblasts, myocytes and tendon. MSCs can also be extracted from blood, fallopian tube, fetal liver and lungs.

Related Journals ofMesenchymal Stem Cells

Insights in Stem Cells, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, Journal of Stem Cells and Regenerative Medicine, Stem Cells and Cloning: Advances and Applications, International Journal of Hematology-Oncology and Stem Cell Research

They are the multipotent stem cells derived from mesoderm and located in red bone marrow. They are responsible for production of red blood cells, white blood cells and platelets. HSCs give rise to myeloid lineage (which forms erythrocytes, eosinophils, basophils, neutrophils, macrophages, mast cells and platelets) and lymphoid lineage (which forms T-lymphocytes, plasma cells and NK cells).

Related Journals ofHematopoietic Stem Cells

Insights in Stem Cells, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, International Journal of Hematology-Oncology and Stem Cell Research, Open Stem Cell Journal, Stem Cell, Stem Cell Research Journal

They can differentiate into more than one cell type, but only into a limited number of cell types. Hematopoietic stem cells are considered multipotent as they can differentite into red blood cells, platelets, white blood cells but they cannot differentiate into hepatocytes or brain cells.

Related Journals ofMultipotent Stem Cells

Cancer Medicine & Anti Cancer Drugs, Colorectal Cancer: Open Access, Reproductive Medicine, Genetics & Stem Cell Biology, Blood, Journal of Cerebral Blood Flow and Metabolism, Biology of Blood and Marrow Transplantation, Pediatric Blood and Cancer, Blood Cells, Molecules, and Diseases, Blood Reviews

Cells with stem cell like abilities have been observed breast cancer, colon cancer, leukemia, melanoma, prostate cancer which can form new cells and lead to tumorigenesis. They cause relapse and metastasis by giving rise to new tumors. Scientists are developing methods to destroy CSCs in place of traditional methods which focus on bulk of cancer cells.

Related Journals ofCancer Stem Cells

Head and Neck Cancer Research, Lung Cancer Diagnosis & Treatment, Genetics & Stem Cell Biology, Cancer Research, Nature Reviews Cancer, Journal of the National Cancer Institute, Clinical Cancer Research, Cancer Cell, Cancer, International Journal of Cancer, British Journal of Cancer

They are derived from Hematopoietic stem cells. They differentiate into Erythrocyte progenitor cell (forms erythrocytes), Thrombocyte progenitor cell (forms platelets) and Granulocyte-Monocyte progenitor cell (forms monocytes, macrophages, neutrophils, basophils, eosinophils, dendritic cells).

Related Journals ofMyeloid Stem cells

Insights in Stem Cells, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, Clinical Medicine Insights: Blood Disorders, Electrolyte and Blood Pressure, Integrated Blood Pressure Control, Indian Journal of Hematology and Blood Transfusion, Current Studies in Hematology and Blood Transfusion, Blood Research, High Blood Pressure and Cardiovascular Prevention, Blood Cancer Journal, BMC Blood Disorders, Blood Transfusion

They are the self-renewing, multipotent stem cells in the nervous system that differentiate into neurons, astrocytes and oligodendrocytes. They repair the nervous system after damage or an injury. They have potential clinical use the management of Parkinsons disease, Huntingtons disease and multiple sclerosis.

Related Journals ofNeural Stem Cells

Oncology & Cancer Case Reports, Prostate Cancer, Reproductive Medicine, Genetics & Stem Cell Biology, Journal of Nervous and Mental Disease, Cortex; a journal devoted to the study of the nervous system and behavior, Child's Nervous System, Journal of the Peripheral Nervous System, Central Nervous System Agents in Medicinal Chemistry

They are derived from embryo in the blastocyst stage. They are pluripotent stem cells. They give rise to all derivatives of the three primary germ layers: endoderm (stomach, colon, liver, pancreas, intestines etc.), mesoderm (muscle, bone, cartilage, connective tissue, lymphatic system, circulatory system, genitourinary system etc.) and ectoderm (brain, spinal cord, epidermis etc.).

Related Journals ofEmbryonic Stem Cells

Human Genetics & Embryology, Breast Cancer: Current Research, Reproductive Medicine, Genetics & Stem Cell Biology, Birth Defects Research Part C - Embryo Today: Reviews, Advances in Anatomy Embryology and Cell Biology, Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia, Italian Journal of Anatomy and Embryology, Romanian Journal of Morphology and Embryology, Neuroembryology, Neuroembryology and Aging

Embryonic stem cells are derived from the fetus are used in treatment of various diseases. As ESCs are pluripotent, they can differentiate into any cell type. Researchers are able to grow ESCs into complex cells types like pancreatic -cells and cardiocytes. Fetal cell therapy is generating lot of controversy from religious groups and ethics committees.

Related Journals ofFetal Stem Cell Therapy

Insights in Stem Cells, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, Archives of Disease in Childhood: Fetal and Neonatal Edition, Seminars in Fetal and Neonatal Medicine, Journal of Maternal-Fetal and Neonatal Medicine, Fetal Diagnosis and Therapy, Journal of Maternal-Fetal Medicine, Fetal and Pediatric Pathology, Fetal and Maternal Medicine Review, Journal of Maternal-Fetal Investigation, International Journal of Infertility and Fetal Medicine

Research is being done to use stem cells for the treatment of diabetes mellitus. Human embryonic stem cells may be grown in vivo and stimulated to produce pancreatic -cells and later transplanted to the patient. Its success depends on response of the patients immune system and ability of the transplanted cells to proliferate, differentiate and integrate with the target tissue.

Related Journals of Stem Cell Therapy for Diabetes

Endocrinology & Diabetes Research, Diabetes & Metabolism, Reproductive Medicine, Genetics & Stem Cell Biology, Diabetes Care, Diabetes, Diabetes, Obesity and Metabolism, The Lancet Diabetes and Endocrinology, Endocrine-Related Cancer, Best Practice and Research in Clinical Endocrinology and Metabolism, Journal of Endocrinology

The procedure to replace damaged cells (in cancers, aplastic anemia etc.) with healthy stem cells of the same person or in another compatible person to restore the normal production of cells. It can either be autologous or allogeneic. Bone marrow HSCs are generally used for the transplantation.

Related Journals of Stem Cell Transplant

Cancer Diagnosis, Cancer Science & Therapy, Cervical Cancer: Open Access, Gastrointestinal Cancer and Stromal Tumors, Genetics & Stem Cell Biology, Cell Transplantation, Journal of Cell Biology, Nature Reviews Molecular Cell Biology, Molecular Cell, Nature Cell Biology, Molecular and Cellular Biology, Cancer Cell, Current Opinion in Cell Biology

They are the totipotent, undifferentiated cells present in the meristems (shoot and root apices) of a plant. They never undergo aging process and can grow into any cell in the plant throughout its lifetime. They have numerous applications in production of cosmetics, perfumes, pigments, insecticides and antimicrobials.

Related Journals ofPlant Stem Cells

Plant Pathology & Microbiology, Plant Biochemistry & Physiology, Plant Physiology & Pathology, Genetics & Stem Cell Biology, Plant Cell, Plant Physiology, Plant Journal, Trends in Plant Science, Current Opinion in Plant Biology, Plant, Cell and Environment, American Journal of Transplantation, Plant Molecular Biology

Several types of dental stem cells have been isolated from mature and immature teeth, exfoliated deciduous teeth and apical papilla, MSCS from tooth germs and from human periodontal ligament. They are found to be multipotent and can give rise to osteogenic, adipogenic, myogenic and neurogenic cell lineages.

Related Journals of Dental Stem Cells

Oral Health and Dental Management, Research & Reviews: Journal of Dental Sciences, Dental Implants and Dentures: open access, Genetics & Stem Cell Biology, International Endodontic Journal, Dental Materials, Caries Research, Journal of Endodontics, Monographs in Oral Science, Molecular Oral Microbiology, Journal of Dentistry,International journal of oral science

Adipose tissue is a huge source of mesenchymal stem cells which differentiate into various cell types. They can be easily extracted in large numbers by a simple lipo-aspiration. They have good application potential in regenerative medicine. ASCs are found to have the ability to differentiate into bone cells, cartilage cells, nerve cells, adipocytes etc.

Related Journals of Adipose Derived Stem Cells

Childhood Obesity, Obesity and Eating Disorders, Reproductive Medicine, Genetics & Stem Cell Biology, International Journal of Obesity, Obesity, Obesity Surgery, Obesity Reviews, Diabetes, Obesity and Metabolism, Diabetes, Obesity and Metabolism, Surgery for Obesity and Related Diseases, Pediatric obesity

Preservation of stem cells is critical for both research and clinical application of stem-cell based therapies. Properly preserved stem cells can be later used in the field of regenerative medicine for treating congenital disorders, heart defects etc. Currently there is no universal method for preserving stem cells and the existing methods are expensive.

Related Journals ofStem Cell Preservation

Oncology & Cancer Case Reports, Prostate Cancer, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, Journal of Stem Cells and Regenerative Medicine, Stem Cells and Cloning: Advances and Applications, International Journal of Hematology-Oncology and Stem Cell Research, Open Stem Cell Journal, Stem Cell, Stem Cell Research Journal

MSCs can be applied in osteoarthritis treatment through implantation and microfracture as well as intra-articular injections. Single injection studies have showed improvement from pain which decreased overtime. Multiple, regular MSC injections into joints may be necessary.

Related Journals ofStem Cell Therapy for Osteoarthritis

Osteoporosis and Physical Activity, Osteoarthritis, Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biology, Osteoarthritis and Cartilage, Arthritis and Rheumatism, Arthritis Care and Research, Arthritis Research and Therapy, Seminars in Arthritis and Rheumatism

OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge peer reviewed Open Access Journals and organizes over 1000 International Conferences annually all over the world. OMICS International journals have over 10 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed an agreement with more than 1000 International Societies to make healthcare information Open Access. OMICS International Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations.

Read the original:
Journal of Stem Cell Research and Therapy - Open Access ...

Read More...

Stem Cell Cancer Treatment in Panama City, Panama

Friday, July 13th, 2018

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

Stem cell cancer treatment

Stem cell cancer treatment is a type of treatment that treats cancer by using stem cell transplant, which is also called peripheral blood stem cell transplant. It is used to try and cure some types of cancer such as myeloma, lymphoma and leukemia. Stem cells are very early blood cells in the bone marrow that develop into red blood cells, white blood cells and platelets. They are needed in order to survive. Your doctor can collect them from a donor or from your blood. After a high dose of treatment which leaves stem cells dead, the stem cells are replaced through an intravenous drip.

Stem cell transplant infuses healthy stem cells into the body to stimulate bone marrow growth, suppress the disease and reduce the possibility of going into remission. Stem cell transplant implies that you can have higher doses of treatment through chemotherapy and radiotherapy. Therefore, the chances of getting cured are higher.

There are two main types of stem cell transplants. You and your doctor will discuss the best choice for you.

This is also known as auto stem cell transplant. Cancer treatment using autologous stem cell transplant uses your own stem cells. It is used mainly to treat myeloma and lymphoma. There is less risk of rejection or graft-versus-host disease, whereby the new donor cells think your cells are foreign and attack them. Ina addition, engraftment is quicker ad side effects are fewer.

How It Works: Your team of doctors collect, freeze and store your own stem cells. You then undergo treatment with chemotherapy or radiation therapy after which your stem cells are thawed and transplanted back into you. You may need to go through the above process twice instead of once. This is known as a tandem or double autologous stem cell transplant.

This type of stem cell transplant is also known as allo stem cell transplant. It involves using stem cells that have been donated. It is mainly used to treat leukemia, aggressive lymphomas and autologous transplants that have failed.

How It Works: Stem cells are donated from a matched donor. You then receive treatment using chemotherapy or radiation therapy after which you receive the donor stem cells.

The type and strength of your high-dose treatment is what will influence any side effects you may have and their severity. Possible side effects include:

After having a stem cell transplant to treat your cancer, you will have regular tests to check your general health. In addition, monitoring the levels of your blood cells, you will have blood tests. Most of the side effects are worse when your blood count is at its lowest. However, as this goes up, the side effects will begin to improve. You will be able to go home when your blood count has reached a safe level.

See the rest here:
Stem Cell Cancer Treatment in Panama City, Panama

Read More...

Stem Cell Therapy for Autism in Panama – Medical Tourism

Wednesday, July 4th, 2018

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

What is autism?

Autism is an array of disorders which are characterized by visible abnormalities in social interactions and communication. The common medical findings associated in children with the disorder are a chronic immunologically mediated inflammatory condition in the gut and reduced oxygenation in specific areas of the brain.

Current research aims at attempting to reverse the abnormalities through administration of anti-inflammatory agents, antibiotic and hyperbaric oxygen. However, none of these approaches address the underlying causes of the intestinal inflammation or oxygen deprivation.

It is thought that mesenchymal stem cells may help reverse inflammatory conditions and regulate the immune system. The umbilical cord-derived mesenchymal stem cells are administered intravenously by a licensed doctor.

Adult stem cells used to treat autism are harvested from human umbilical cord tissue also called allogenic mesenchymal. The human umbilical cords are donated by mothers after healthy and normal births. They are thoroughly screened and tested for bacteria and viruses.

They are idea for the treatment of autism because they allow for the administering of uniform doses and do not necessitate any stem cell harvesting from the patient, which can be quite concerning for the parents and terrifying for the autistic child. Because the stem cells are collected immediately after birth the umbilical cord-derived cells are much more effective than their counterparts such as bone marrow derived cells.

In addition the umbilical cord derived mesenchymal cells are not rejected by the patient because they do not recognize them as foreign. This is due to the fact that the HUCT stem cells are less mature than other cells. HUCT stem cells also differentiate/proliferate better that older cells and are therefore considered to be more potent.

A typical autism treatment protocol takes about 5 days and involves blood tests and physical examination. Intravenous infusions of the mesenchymal cells are then administered.

The cells are not rejected because the HUCT mesenchymal stem cells are immune system privileged and Human Leukocyte (HLA) matching is not required.

Screening and testing of the best stem cells can be conducted to ensure that the best immune modulating capacity, anti-inflammatory and regeneration stimulation cells are selected.

Administering of uniform dosages with high cell counts can be done with the allogenic stem cells.

The umbilical cord tissue provides a supply of mesenchymal stem cells in abundance.

There is no need to harvest stem cells from the patient under anesthesia which can be very unpleasant t the child.

Umbilical cord-derived mesenchymal stem cells are thought by researchers to be more robust than mesenchymal stem cells harvested from other sources.

Proper follow up after the procedure is necessary to ensure that the patient is progressing well.

The rest is here:
Stem Cell Therapy for Autism in Panama - Medical Tourism

Read More...

Stem Cell Therapy A Rising Tide Neil H. RIordan, PA …

Wednesday, June 20th, 2018

By Neil H. Riordan, PA, PhD

Autism, spinal cord injury, arthritis, multiple sclerosis . . . At first glance, these incurable conditions, devastating and life-altering for patients and their families, have little in common clinically. But each condition responds well to a cutting-edge, research-based therapy that is changing patients lives when conventional medicine has failed them.

The body has a built-in healing ability determined by the presence and quality of its stem cells. When those cells are not numerous or robust enough to maintain health, chronic disease sets in. In other cases, children begin life with an unfair disadvantage in the form of autism, muscular dystrophy, or cerebral palsy. Still others experience certain debilitating injuries that dont respond to surgery or physical therapy. For all of these conditions, and more, stem cell therapy is shortening the path to wellness.

The lives of millions of people are at stake.

Neil Riordan PA, PhD has spent over thirty years pioneering the research and development of evidence-based biologic technologies to successfully treatand sometimes reversea wide range of health conditions. Neils rigorous dedication to bringing stem cell therapy out of the shadows and into mainstream medicine is not only an interesting story, but also a powerful call to action for patients, lawmakers, and the medical community at large.

From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, patients are experiencing health transformations that mainstream medicine was unable to achieve. Many of them had lost all hope.These are their stories.

Neil takes readers on a riveting journey through the past, present and future of stem cell therapy.Hiswell-researched, educational and entertaining book could change your life.I highly recommend it.

Neil is certainly a student of the medical arts and an expert using innovative treatments. I have talked to patients of Neils clinics and their family members about their treatments; the stories told in this book are just the tip of the iceberg. This is an interesting book and an interesting and gutsy journey of Neil Riordan. His physician father would be proud to recognize Neils passion and medical achievements.

Read the original:
Stem Cell Therapy A Rising Tide Neil H. RIordan, PA ...

Read More...

Stem Cell Cancer Treatment in Panama – health-tourism.com

Wednesday, September 20th, 2017

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

Stem cell cancer treatment

Stem cell cancer treatment is a type of treatment that treats cancer by using stem cell transplant, which is also called peripheral blood stem cell transplant. It is used to try and cure some types of cancer such as myeloma, lymphoma and leukemia. Stem cells are very early blood cells in the bone marrow that develop into red blood cells, white blood cells and platelets. They are needed in order to survive. Your doctor can collect them from a donor or from your blood. After a high dose of treatment which leaves stem cells dead, the stem cells are replaced through an intravenous drip.

Stem cell transplant infuses healthy stem cells into the body to stimulate bone marrow growth, suppress the disease and reduce the possibility of going into remission. Stem cell transplant implies that you can have higher doses of treatment through chemotherapy and radiotherapy. Therefore, the chances of getting cured are higher.

There are two main types of stem cell transplants. You and your doctor will discuss the best choice for you.

This is also known as auto stem cell transplant. Cancer treatment using autologous stem cell transplant uses your own stem cells. It is used mainly to treat myeloma and lymphoma. There is less risk of rejection or graft-versus-host disease, whereby the new donor cells think your cells are foreign and attack them. Ina addition, engraftment is quicker ad side effects are fewer.

How It Works: Your team of doctors collect, freeze and store your own stem cells. You then undergo treatment with chemotherapy or radiation therapy after which your stem cells are thawed and transplanted back into you. You may need to go through the above process twice instead of once. This is known as a tandem or double autologous stem cell transplant.

This type of stem cell transplant is also known as allo stem cell transplant. It involves using stem cells that have been donated. It is mainly used to treat leukemia, aggressive lymphomas and autologous transplants that have failed.

How It Works: Stem cells are donated from a matched donor. You then receive treatment using chemotherapy or radiation therapy after which you receive the donor stem cells.

The type and strength of your high-dose treatment is what will influence any side effects you may have and their severity. Possible side effects include:

After having a stem cell transplant to treat your cancer, you will have regular tests to check your general health. In addition, monitoring the levels of your blood cells, you will have blood tests. Most of the side effects are worse when your blood count is at its lowest. However, as this goes up, the side effects will begin to improve. You will be able to go home when your blood count has reached a safe level.

Here is the original post:
Stem Cell Cancer Treatment in Panama - health-tourism.com

Read More...

On the trail of yellow fever – Science Magazine

Thursday, August 17th, 2017

Monkeys and mosquitoes hold clues to when and where the virus could resurge in Brazil.

Researchers Bruna Sena Nascimento (foreground) and Hlio Saraiva climb a tree to capture mosquitoes in the canopy in Santa Barbara, Brazil.

The howler monkeys slink like cats through the canopy, swiveling their heads to look for danger. They have reason to be wary. In the jungle below, biologists armed with a black tranquilizer rifle are hunting them, flashes of khaki through the foliage.

The scientists signal each other with snaps and whistles and pivot directions frequently; they often cross trails perpendicularly instead of following them. As they maneuver for clean shots, thick leaves come rattling down through the branches. In the distance, marmosets whistle.

The scientists are on Ilha Grande, an island off southern Brazil that once housed a notorious maximum security prison. Resorts dot the perimeter today, but untouched jungle dominates the interior. Brazil recently experienced its worst outbreak of yellow fever in decades with hundreds of cases, some just east of Ilha Grande. So scientists plan to test local howler monkeys (called bugios) for the virus to learn whether it has spread here, too. If they can catch one.

Suddenly, a shota sharp hiss. A 20-centimeter dart with a red tuft for a tail rockets upward. The shooter is Filipe Abreu, a Ph.D. student at the Oswaldo Cruz Foundation (Fiocruz), a research institute in Rio de Janeiro, Brazil. Abreu looks as if he's been in the wild for weeks: muddy pants, scruffy beard, machete dangling from his belt. He's an entomologist, but the intricate transmission cycle of yellow fever, which involves both monkeys and mosquitoes, compels him to study primates, too.

The shot misses. Instead of leaves, the dart comes clattering down. A second shot also goes awry, striking a branch and bending the needle tip 45.

The party regroups, and Abreu hands the rifle to Marcelo Quintela Gomes, a technician at Fiocruz. The hunters thread through vines and shinny down trees into a gully. Every so often Gomes raises the rifle, then drops it. He eventually takes three shots, all misses. Everyone agrees that the bugios are unusually skittish.

They're not the only ones. Yellow fever has left the people of Brazil feeling edgy as well. Over the past 8 months, they've endured vaccine shortages, lurid media stories, and the occasional slaughter of innocent monkeys. To stem such problems, scientists have scoured this massive country to figure out where the virus lurks and how it's spreadingknowledge vital to fighting future outbreaks as well. But fear remains, especially the fear that yellow fever will ravage the megacities along Brazil's east coastor push even beyond that.

We've seen Zika march up to the United States, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, in Geneva, Switzerland. So have dengue fever, chikungunya, and other mosquito-borne diseases. There's no reason to think yellow fever won't do the same, he says.

YELLOW FEVER WAS ONCE the world's most feared disease. Most victims suffer only fevers and aching joints, but 15% get walloped: Their eyes and skin turn yellow, and they bleed from the mouth and eyes. (The Spanish name for the disease, vomito negro, means black vomit.) No drugs exist to treat it, and half of those who develop the serious form die as the virus destroys their livers.

Native to Africa, yellow fever spread to the Americas with the slave trade. In 1793, then-President George Washington fled Philadelphia, Pennsylvania (then the U.S. capital), during an epidemic that killed 5000. Later outbreaks nearly derailed the construction of the Panama Canal.

A vaccine developed in the 1930s largely eliminated the disease in North America. Africa and South America, meanwhile, continue to suffer. Sub-Saharan Africa accounts for 90% of cases, including a 2016 outbreak centered in Angola with thousands of victims. But in some ways yellow fever in South America is scarier: Because of the low natural immunity there, it kills one-third of those who contract it.

Brazil seems particularly vulnerable. Yellow fever long ago disappeared into the interior, and given the mere handful of cases most years (2014 saw none at all), few people outside endemic areas get vaccines. But in December 2016, victims began appearing in the east for the first time since 1942. The government confirmed 792 cases in 130 cities nationwide, with several hundred more under investigation. More than half occurred in Minas Gerais (population: 21 million), a southeastern state bordering the states of Rio de Janeiro (17 million) and So Paulo (44 million). One victim reportedly died within 40 kilometers of the city of Rio.

State health ministries, which administer vaccines, have ordered 26.3 million emergency doses since December, but some places still ran short. During Carnival in February, a squirrel monkey died of yellow fever in Utinga State Park in Belm in northern Brazil. After panicked stories in the press, people stampeded vaccine clinics, which had to open extra rooms to contain the crowds. After 12,000 inoculations in 5 days, Belm's clinics exhausted their supply.

Although the onset of winter slowed the outbreak, scientists fear a resurgence next year. When and where it might reappear depends on the erratic and often maddening behavior of three animals: mosquitoes, monkeys, and humans.

TWO TRANSMISSION CYCLES of yellow fever exist in South America. In the sylvatic (jungle) cycle, mosquitoes from two generaSabethes and Haemagogusspread the virus mostly between monkeys, with people (usually loggers or miners in remote areas) bitten and infected only incidentally. But the possibility of an urban cycle looms. Here, a different mosquito, the infamous Aedes aegypti, spreads the disease directly from person to person, and cases quickly multiply. All the recent cases in Brazil have been sylvatica slight misnomer because some have occurred inside citiesbut no human-to-human transmission has occurred.

Bruna Sena Nascimento brings the mosquitoes she catches in the forest (top) back to a lab at the Evandro Chagas Institute in Belm, Brazil (bottom), where she identifies the species and checks for signs of the yellow fever virus.

Pinning down which mosquito species carry the virus can yield clues about who is at risk and where. So on a recent June morning, entomologists from the Evandro Chagas Institute in Belm don green jumpsuits and drive north to the jungle. On the way, they swap stories about all the mosquito-borne diseases they've endured. Leathery old Hlio Saraiva has had three strains of dengue.

They park at a dilapidated banana farm and start gathering equipment. Just in case, bring the big knife, someone says. Saraiva grabs a 45-centimeter machete with ENTOMOLOGIA on the scabbard. As they head off, the farm's resident Dalmatian trots up to join the adventure.

After several turns, they stop. Twelve meters above is a platformor rather, four ragged planks. Yellow fever mosquitoes dine on monkeys in the canopy, so researchers have to scale trees, too. There's no ladder, just a few dozen nails pounded into the trunk to hoist yourself up. It's a drenching climb in the heat.

An ignorant reporter asks what they use for mosquito bait. Bruna Sena Nascimento, an animated entomologist, laughs. We are the bait. Oh. Mosquitoes are attracted to the carbon dioxide that primates exhale. So unlike with monkeys, hunting mosquitoes is easy: Just sit and waitand hold off on the bug spray.

In the old days, researchers sometimes sat on platforms in their underwear, counting bites and noting what parts of the body mosquitoes preferred. Now, fully clothed scientists use short white nets to nab mosquitoes in the air. They then slip tubes into the nets, suck the bugs up with their lungs, and puff them out into collection vesselsanything from sawed-off sections of PVC pipe to plastic Teenage Mutant Ninja Turtles cups with lids. (Entomology is a cheap science, Abreu says. You improvise.) A half-day in the canopy can net a few hundred skeeters.

Back at the lab in Belm, Nascimento freezes and sorts her mosquitoes, focusing on the abdominal stripes or sweeping back legs that distinguish various species. After the sorting, the mosquitoes go into vials filled with saline and a BB. An automatic agitator then liquefies the bugs, producing a foamy gray ink with floating legs. The fluid is added to cell cultures to test for yellow fever.

Although scientists know the disease's main vectors in Brazil, they're still investigating whether others play a role. One mystery is how outbreaks shift from sylvatic to urban and what species drive that shift. Perhaps miners or loggers simply carry the virus back to cities. But certain mosquitoes might play a role, too. Abreu suspects that A. albopictus, the Asian tiger mosquito, which often straddles jungle and urban areas, might harbor the virus and could bridge the cycles by introducing cases into new areas.

Even the known vectors wreak plenty of havoc, though. Says Thomas Monath, a yellow fever expert at NewLink Genetics, a biotech company in Ames, Iowa: In Brazil, they've drawn a line that supposedly demarcates risk. We vaccinate people on one side and don't vaccinate people living on the other side. But mosquitoes aren't observing that demarcation.

IF MOSQUITOES ARE THE VILLAINS of yellow fever, monkeys are the main victims. A lack of natural immunity leads to devastating outbreaks for many South American species, especially howler monkeys. In the throes of the disease, Abreu says, they often descend from trees to riverbanks to slake their thirst, but lack the strength to climb up again. They end up shivering in the dirt, wracked with pain.

During the Brazilian outbreak, health officials nationwide asked people to report sightings of sick or dead monkeys so they could test for yellow fever. They received reports of 5300 dead monkeys since the outbreak started, with an unknown number related to yellow fever. Biologists also carried out active vigilance campaigns, such as the hunts on Ilha Grande.

Shooting monkeys on those hunts is only half the challenge. After the tranquilizer hits, scientists have about 5 minutes before the monkey passes out and plummetsduring which time they're scrambling about with a net, hoping like crazy it doesn't wander into some inaccessible area. Once it lands safely, they check its gums, eyes, and genitals for yellow discoloration, then take blood from the groin to test for virus. Although the monkey usually wakes within an hour, it might remain loopy for several more, rendering it vulnerable to falling or a jaguar attack. So scientists usually detain itone group uses a red dog carrieruntil it recovers its wits.

Most people in Brazil know that monkeys can catch yellow fever. Alas, many also believe that monkeys infect people, which isn't true. (Mosquitoes do.) As a result, people in rural areas sometimes shoot monkeys or leave poisoned fruit around, adding dozens of casualties to an already devastating outbreak. Killing monkeys ends up harming humans as well, says Jlio Bicca-Marques, a primatologist at the Pontifical Catholic University of Rio Grande do Sul in Porto Alegre, Brazil: The death of monkeys from yellow fever is the first warning that the virus is circulating. In other words, monkeys are sentinels, he says, early detection systems. Without the monkeys in our forests, we'll be blind.

HUMAN BEINGS, the third actor in this drama, are the least predictable. Miners and loggers, some with fake immunization cards, jet between sylvatic regions and cities in just hours, potentially transferring the virus to new areas. Cutting down forests also exposes people to mosquitoes that would otherwise remain hidden.

Building homes in forest clearings, a common practice in Brazil, is especially risky. On one side of the road might sit shanties with chickens wandering about and satellite dishes anchored onto mossy boulders. On the other, a wall of thick jungle with vibrant red tropical birds and playful monkeys. Jozelene Beckmann, who lives in Belm, home of the state park where the squirrel monkey died, says that monkeys used to cavort along her rooftop and slip inside her home. Unfortunately, where monkeys go, mosquitoes followas does yellow fever. After years of ignoring recommendations, Beckmann finally got vaccinated in mid-June.

Briefly anesthetized, a monkey has its blood drawn to check for yellow fever virus.

Vaccinating infants for yellow fever is already mandatory in northern and Amazonian states, where the disease is endemic, and some scientists propose extending the law nationwide. But because vaccination carries a small riskone in 300,000 people develops full-blown yellow fever after vaccination and another one in 100,000 develops meningitisthe government has stopped short of mandating it for everyone, instead merely recommending it. Many people in Rio and other cities ignore the recommendation. One problem is that most vaccine clinics keep short hours, and with the Brazilian economy struggling, people can't take time off work to visit.

The low compliance frustrates scientists because inoculation could basically eliminate yellow fever nationwide, and do so at a pittance. A single dose given as an infant that costs a dollar is effective for life. That's extraordinary, Monath says. During the Angolan emergency last year, health officials stretched vaccine supplies with fractional doses of one-fifth the normal amount, and even that seemed to offer short-term protection.

Still, making the vaccine has its challenges. It's hard to scale up production, for one thing, partly because many steps are still performed by hand, the same basic way they were in the 1930s. Manufacturers grow the virus in chicken eggs, which workers must candle one by one with hand lamps to check for signs of live embryosveins, eyes, movement. (Dead eggs are discarded.) A single technician might examine 8000 eggs per week. Technicians also must burn holes in the eggshells with torches to introduce the virus, and later burn more holes around the waist of the egg to extract the infected embryos for grinding in blenders. It's not quite artisanal vaccine production, but it's close.

Another problem is more perverse: The vaccine is almost too good at preventing yellow fever. Because it costs so little and protects people for life, making it isn't profitable. Worldwide, just four institutes bother, including Fiocruz. Manufacturers also dislike the uneven market for it: low demand most years, followed by outbreaks that leave them scrambling. Production at Fiocruz, for instance, jumped from 25 million doses in 2016 to a planned 70 million this yearwhich forced the institute to cut back severely on its vaccine for measles, mumps, and rubella.

The market could soon change, however. The World Health Organization (WHO) recently brokered deals in several African and South American countries to vaccinate 584 million people for yellow fever over the next decade, with a goal of eliminating all outbreaks worldwide by 2026. That campaign should steady the market by ensuring stable demand. To boost supply, Fiocruz is also building a new $1 billion plant west of Rio that, in a few years, could produce up to 100 million doses of yellow fever vaccine annually.

Still, WHO notes that production of vaccine almost always lags behind projections. Lack of urgency among political leaders could also weaken the campaign. Public health authorities, says Monath, can basically forget about [the disease] in between these horrible episodes. So although the new Fiocruz facility will help, eliminating outbreaks worldwide remains an ambitious goal. The quick spread of Zika and other mosquito-borne diseases from South America up to Texas and Florida also suggests that yellow fever will be hard to tame.

During the yellow fever outbreak this year, public health clinics in Belm, Brazil, vaccinated hundreds of people daily.

But the danger of yellow fever in North America pales in comparison with the disaster that could arise if it ever spread to Asia. Even though southern Asia has all the prerequisites for yellow fevermonkeys, mosquitoes, a warm climatethe disease has never gained a foothold on the world's most populous continent. Perhaps, some scientists speculate, other diseases there provide cross-immunity. Or perhaps humans have simply been lucky. But last year, 11 Chinese men working in Angola developed yellow fever upon returning home, the first confirmed cases in Asian history. Thankfully, the disease spread no further. But if the urban cycle ever got established there, 1.8 billion peoplevirtually all unvaccinated and presumably with high genetic susceptibilitycould be vulnerable.

Moreover, the struggle to contain yellow fever, a familiar disease with an effective vaccine, does not augur well for our ability to combat the new diseases that will almost certainly emerge as people push deeper into jungles. As Jon Abramson, a pediatrician at Wake Forest University in Winston-Salem, North Carolina, and a yellow fever adviser for WHO, puts it: If we can't stop outbreaks with yellow fever, we're in a lot of trouble with other outbreaks.

IN BRAZIL, the quest to stop the current outbreak continues. On Ilha Grande, after the howler monkeys scatter, the hunting party takes a break to catch insects. Sometimes we get mosquitoes and can't get monkeys; other times, we get monkeys but can't get mosquitoes, Abreu says philosophically. Both are important.

But after tracking those two creatures all morning, Abreu and Gomes now switch their attention to the final animal in the yellow fever triad: humans. To that end, they visit the abandoned prison nearby, now a museum.

Locals there are gossiping about a tourist who recently found a dead monkey nearby and posted a picture on Facebook. Unfortunately, something dragged the carcass off before authorities could test it for yellow fever.

Abreu befriends the museum guard, whose backyard is a popular crossing point for monkeys. She's quite taken with the tranquilizer rifle, and he shows her how it works. Afterward they exchange contact information, so she can alert him if she sees sick or dead monkeys. She then asks Abreu whether it's true that monkeys give yellow fever to humans. He assures her that they don't.

Late the next morning, Gomes finally bags a bugio, a female. Instead of tumbling from the canopy, she slides down a thick shaft of bamboo like that pole the firemen come down, Abreu says. But she is unharmed, and they get a good blood sample.

A few weeks later, the results come back: negative for yellow fever. That's a reliefno sign yet that this ancient scourge has infiltrated the island paradise. But with nearby mainland cities confirming cases and tourists pouring in, it might not be long. As the rest of Brazil has shown, exemption from yellow fever today is no guarantee of a safe tomorrow.

Link:
On the trail of yellow fever - Science Magazine

Read More...

New method to 3D print living tissues developed – Livemint

Thursday, August 17th, 2017

Scientists at the University of Oxford in the UK devised a way to produce tissues in self-contained cells that support the structures to keep their shape. Photo: iStock

London: Oxford scientists have developed a new method to 3D-print laboratory-grown cells to form living structures, an advance that may help repair damaged body parts. The approach could revolutionise regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body, researchers said.

Scientists at the University of Oxford in the UK devised a way to produce tissues in self-contained cells that support the structures to keep their shape. The cells were contained within protective nanolitre droplets wrapped in a lipid coating that could be assembled, layer-by-layer, into living structures. Producing printed tissues in this way improves the survival rate of the individual cells, and allowed the team to improve on current techniques by building each tissue one drop at a time to a more favourable resolution.

To be useful, artificial tissues need to be able to mimic the behaviours and functions of the human body, researchers said. The method enables the fabrication of patterned cellular constructs, which, once fully grown, mimic or potentially enhance natural tissues.

We were aiming to fabricate three-dimensional living tissues that could display the basic behaviours and physiology found in natural organisms, said Alexander Graham, scientist at OxSyBio (Oxford Synthetic Biology).

To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells, said Graham. The research was published in the journal Scientific Reports.

Excerpt from:
New method to 3D print living tissues developed - Livemint

Read More...

Stem Cell Therapy || Patient Treatment Disclaimer || Stem …

Saturday, August 5th, 2017

Click the YES button at the bottom of this page to continue.

This website http://www.cellmedicine.com offers patients, doctors and scientists the opportunity to connect to licensed doctors who use adult stem cells as part of their clinical practice outside of the United States and Canada. Because stem cell therapy is not the standard of care in the US or Canada, the following important disclosures are made:

1) The Stem Cell Institute is not conducting free clinical trials at this time.2) Health insurance will not cover the treatment fees.3) The Stem Cell Institute does not provide itemized bills.

Treatments include from 3 to 16 separate stem cell infusions/injections over the course of 4 to 30 days depending upon the protocol employed. A fee will be quoted once your treatment protocol has been determined.We DO NOT treat:

JavaScript is disabled! Please enable JavaScript and then reload this form before you begin. If you cannot do this on your own, please call 1-800-980-STEM and we will arrange for someone to email an application to you. Thank you.

To access the application you must first agree that you have read and understand all of the statements above.

I have read and understand all of the statements above:

Continued here:
Stem Cell Therapy || Patient Treatment Disclaimer || Stem ...

Read More...

Page 3«..2345..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick